<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92889</article-id><article-id pub-id-type="doi">10.7554/eLife.92889</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.92889.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Senescence of endplate osteoclasts induces sensory innervation and spinal pain</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-336574"><name><surname>Pan</surname><given-names>Dayu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0284-9350</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-336577"><name><surname>Benkato</surname><given-names>Kheiria Gamal</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-336578"><name><surname>Han</surname><given-names>Xuequan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5629-5918</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-336581"><name><surname>Zheng</surname><given-names>Jinjian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-336579"><name><surname>Kumar</surname><given-names>Vijay</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-73056"><name><surname>Wan</surname><given-names>Mei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9404-540X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-336580"><name><surname>Zheng</surname><given-names>Junying</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0001-2631-8055</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-31435"><name><surname>Cao</surname><given-names>Xu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8614-6059</contrib-id><email>xcao11@jhmi.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Department of Orthopedic Surgery and Department of Biomedical Engineering, Johns Hopkins University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ryu</surname><given-names>Vitaly</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Behrens</surname><given-names>Timothy E</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>19</day><month>06</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP92889</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-09-21"><day>21</day><month>09</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-10-26"><day>26</day><month>10</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.26.564218"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-11-14"><day>14</day><month>11</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92889.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-04-10"><day>10</day><month>04</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.92889.2"/></event></pub-history><permissions><copyright-statement>Â© 2023, Pan et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Pan et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92889-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-92889-figures-v1.pdf"/><abstract><p>Spinal pain affects individuals of all ages and is the most common musculoskeletal problem globally. Its clinical management remains a challenge as the underlying mechanisms leading to it are still unclear. Here, we report that significantly increased numbers of senescent osteoclasts (SnOCs) are observed in mouse models of spinal hypersensitivity, like lumbar spine instability (LSI) or aging, compared to controls. The larger population of SnOCs is associated with induced sensory nerve innervation, as well as the growth of H-type vessels, in the porous endplate. We show that deletion of senescent cells by administration of the senolytic drug Navitoclax (ABT263) results in significantly less spinal hypersensitivity, spinal degeneration, porosity of the endplate, sensory nerve innervation, and H-type vessel growth in the endplate. We also show that there is significantly increased SnOC-mediated secretion of Netrin-1 and NGF, two well-established sensory nerve growth factors, compared to non-senescent OCs. These findings suggest that pharmacological elimination of SnOCs may be a potent therapy to treat spinal pain.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>low back pain</kwd><kwd>senescence</kwd><kwd>osteoclast</kwd><kwd>sensory nerve</kwd><kwd>endplate</kwd><kwd>H-type vessle</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AG068997</award-id><principal-award-recipient><name><surname>Cao</surname><given-names>Xu</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01AG066603</award-id><principal-award-recipient><name><surname>Cao</surname><given-names>Xu</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AG076783</award-id><principal-award-recipient><name><surname>Cao</surname><given-names>Xu</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AR071432</award-id><principal-award-recipient><name><surname>Cao</surname><given-names>Xu</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Depleting senescent osteoclasts using the senolytic drug Navitoclax (ABT263) can reduce sensory innervation in the endplate and attenuate low back pain, thus representing a potent therapy for treating spinal pain.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Low back pain (LBP) is the most common musculoskeletal problem globally, affecting at least 80% of all individuals at some point in their lifetime (<xref ref-type="bibr" rid="bib14">Chou et al., 2007</xref>; <xref ref-type="bibr" rid="bib16">Deyo et al., 1991</xref>; <xref ref-type="bibr" rid="bib28">Hoy et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Maher et al., 2017</xref>). It has also become the leading cause of years lived with disability worldwide, with almost 65 million cases involved per year (<xref ref-type="bibr" rid="bib11">Chen et al., 2022</xref>; <xref ref-type="bibr" rid="bib29">James et al., 2018</xref>), which consequently results in a tremendous medical burden and economic cost (<xref ref-type="bibr" rid="bib16">Deyo et al., 1991</xref>; <xref ref-type="bibr" rid="bib26">Hartvigsen et al., 2018</xref>). Current pharmacological treatment options for LBP include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioids, etc. (<xref ref-type="bibr" rid="bib50">Qaseem et al., 2017</xref>). However, the clinical use of these medications is limited due to potential severe adverse effects and modest therapeutic efficacy (<xref ref-type="bibr" rid="bib52">Roelofs et al., 2008</xref>; <xref ref-type="bibr" rid="bib17">Deyo et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Goldberg et al., 2015</xref>). Some biological agents aiming for LBP management are under investigation as well (<xref ref-type="bibr" rid="bib54">Sheyn et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Liao et al., 2019</xref>). For example, parathyroid hormone has shown a superior antinociceptive effect on LBP in recent studies (<xref ref-type="bibr" rid="bib10">Chen et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Nevitt et al., 2006</xref>), whereas its risk of causing osteosarcoma and Pagetâs disease is not negligible (<xref ref-type="bibr" rid="bib2">Andrews et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Harper et al., 2007</xref>; <xref ref-type="bibr" rid="bib41">Martin et al., 1976</xref>). Thus, there is an urgent unmet clinical need for effective nonsurgical therapeutic interventions for LBP.</p><p>Cellular senescence is a stable and terminal state of growth arrest in which cells are unable to proliferate despite optimal growth conditions and mitogenic stimuli (<xref ref-type="bibr" rid="bib18">Di Micco et al., 2021</xref>). It can be induced by various triggers, including DNA damage, telomere dysfunction, and organelle stress, and it has been linked to host physiological processes and age-related diseases, such as atherosclerosis, type 2 diabetes, and glaucoma (<xref ref-type="bibr" rid="bib13">Childs et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">He and Sharpless, 2017</xref>; <xref ref-type="bibr" rid="bib33">Krishnamurthy et al., 2006</xref>; <xref ref-type="bibr" rid="bib38">LÃ³pez-OtÃ­n et al., 2013</xref>). Hence, the clearance of senescent cells has been suggested as a promising therapeutic strategy in several areas of pathology. For instance, glomerulosclerosis and decline in renal function in aged mice are rescued by clearance of p16<sup>INK4a</sup>-expressing senescent tubular brush-border epithelial cells, while clearance of senescent cells reduces age-related cardiomyocyte hypertrophy and improves cardiac stress tolerance (<xref ref-type="bibr" rid="bib4">Baker et al., 2016</xref>).</p><p>Likewise, it has been shown that cellular senescence is an essential factor in the promotion of age-related musculoskeletal diseases, such as osteoporosis (<xref ref-type="bibr" rid="bib19">Farr et al., 2017</xref>), osteoarthritis (OA) (<xref ref-type="bibr" rid="bib30">Jeon et al., 2017</xref>), and intervertebral disc (IVD) degeneration (<xref ref-type="bibr" rid="bib12">Cherif et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Wang et al., 2016</xref>). The effectiveness of senolytic drugs towards bone-related diseases via elimination of senescent cells is also well documented (<xref ref-type="bibr" rid="bib19">Farr et al., 2017</xref>). In particular, for the treatment of IVD degeneration, which is strongly associated with LBP, it was demonstrated that the senescent cells of degenerative discs were removed, and the IVD structure was restored by treatment with ABT263, a potent senolytic agent, in an injury-induced IVD degeneration rat model (<xref ref-type="bibr" rid="bib37">Lim et al., 2022</xref>). Furthermore, recent research shows a direct link between telomere shortening-induced cellular senescence and chronic pain hypersensitivity (<xref ref-type="bibr" rid="bib46">Muralidharan et al., 2022</xref>). Previous studies conducted by our laboratory have elucidated the significant role of osteoclasts in initiating the porosity of endplates with sensory innervation into porous areas and triggering LBP (<xref ref-type="bibr" rid="bib48">Ni et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Xue et al., 2021</xref>). Attenuating sensory innervation by inhibiting osteoclast activity could reduce spinal pain sensitivity. Importantly, it has been observed that some osteoclasts exhibit characteristics of senescence during osteoclastogeneses, such as the expression of p16 and p21, appearing to obtain a heterogeneous senescent phenotype (<xref ref-type="bibr" rid="bib34">Kwak et al., 2005</xref>; <xref ref-type="bibr" rid="bib23">Gorissen et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Mizoguchi et al., 2009</xref>). Based on all these findings, we speculated there might be a subgroup of osteoclasts that are senescent (which we refer to as SnOCs), and they might promote the induction of sensory nerve innervation in porous endplates and spinal hypersensitivity.</p><p>Here, we demonstrate the presence of SnOCs in the porous endplates in two different spinal hypersensitivity mouse models induced by aging and LSI, respectively. We then deleted SnOCs in these models with ABT263, which resulted in a decreased number of tartrate-resistant acid phosphatase positive (TRAP<sup>+</sup>) OCs in the endplates along with decreased endplate porosity, reduced sensory innervation, and attenuated spinal pain behaviors. Together, these findings suggest the potential of utilizing senolytic drugs for the treatment of LBP and its associated pathologies.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>A significantly increased number of SnOCs are associated with endplate degeneration and spinal hypersensitivity in the LSI and aged mouse models</title><p>In this study, we used two different LBP mouse models created by LSI and aging. LSI was induced in 3-month-old C57/BL6 mice by surgically resecting the L3âL5 spinous processes along with the supraspinous and interspinous ligaments (<xref ref-type="bibr" rid="bib6">Bian et al., 2016</xref>; <xref ref-type="bibr" rid="bib3">Ariga et al., 2001</xref>; <xref ref-type="bibr" rid="bib43">Miyamoto et al., 1991</xref>). Aged (24-month-old) C57BL/6J male mice were purchased from Jackson Laboratory. To explore spinal hypersensitivity, pain-related behavioral assessments, such as the von Frey test, hot plate test, and active wheel test, were performed on sham-operated mice, LSI mice, and aged mice. In both models, there was significantly less active time, distance traveled, and maximum speeds compared to the sham control (<xref ref-type="fig" rid="fig1">Figure 1aâc</xref>). Additionally, LSI mice and aged mice displayed significantly less reduced heat response times (<xref ref-type="fig" rid="fig1">Figure 1d</xref>), as well as significantly increased frequencies of paw withdrawal (PWF), depending on the strength of the mechanical stimulation, (<xref ref-type="fig" rid="fig1">Figure 1e and f</xref>) compared to the sham mice. By three-dimensional microcomputed tomography (Î¼CT) analysis, we found a significant increase in the porosity and separation of trabecular bone (Tb.Sp) within the endplates of both LSI and aged mice compared to their younger counterparts without LSI (<xref ref-type="fig" rid="fig1">Figure 1g and k</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>A greater number of senescent osteoclasts (SnOCs) are associated with endplate degeneration and spinal hypersensitivity in the lumbar spine instability (LSI) and aged mouse models.</title><p>(<bold>aâc</bold>) Spontaneous activity, including active time (<bold>a</bold>), distance traveled (<bold>b</bold>), and maximum speed (<bold>c</bold>) on the wheel within 48 hr in the sham, LSI injury, and aged mice. (<bold>d</bold>) Time in seconds spent on a hot plate in the three groups of mice. (<bold>e, f</bold>) The frequency of hind paw withdrawal (PWF) in response to mechanical stimulation (von Frey test, 0.07 g (<bold>e</bold>) and 0.4 g (<bold>f</bold>)) in the sham, LSI injury, and aged mice. (<bold>g</bold>) Microcomputed tomography (Î¼CT) images of coronal caudal endplate sections of L4â5 from 3-month-old sham and LSI and 24-month-old aged mice. (<bold>h</bold>) Immunofluorescent (IF) staining of p16 (green), tartrate-resistant acid phosphatase positive (TRAP) (red), and 4â²,6-diamidino-2-phenylindole (DAPI) (blue) of the endplates of sham, LSI, and aged mice. (<bold>i and j</bold>) IF staining of TRAP (red) and DAPI (blue) (<bold>i</bold>) and senescence-associated beta-galactosidase (SA-Î²Gal) (blue) staining (<bold>j</bold>) of endplate serial sections of sham, LSI surgery, and aged mice. (<bold>k and l</bold>) Microcomputed tomography (Î¼CT) quantitative analysis of the porosity percentage (<bold>k</bold>) and trabecular separation (Tb.Sp) (<bold>l</bold>) of the endplates in the indicated groups. (<bold>m</bold>) Number of SnOCs (p16-positive and TRAP-positive cells) per mm2 in the indicated groups. (<bold>n</bold>) Number of SA-Î²Gal (blue) positive cells per mm2 in the endplates in the indicated groups. (<bold>o</bold>) Number of TRAP (red) positive cells per mm2 in the endplates in the indicated groups. nâ¥4 per group. Scale bar, 1 mm (<bold>g</bold>) and 20 Î¼m (<bold>h, i, j</bold>). Statistical significance was determined by one-way ANOVA, and all data are shown as means Â± standard deviations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>Increased occurrence of SnOCs in the endplates of two LBP models compared to the control young sham mice.</title><p>(<bold>a</bold>) Representative images of immunofluorescent analysis of HMGB1, a senescent marker (green), tartrate-resistant acid phosphatase positive (TRAP), an osteoclast marker (red) and nuclei (4â²,6-diamidino-2-phenylindole [DAPI]; blue) of adult sham, lumbar spine instability (LSI), and aged mice. (<bold>b</bold>) Quantitative analysis of the number of TRAP<sup>+</sup>HMGB1<sup>+</sup> senescent osteoclasts (SnOCs) per mm2. nâ¥4 per group. Statistical significance was determined by one-way ANOVA, and all data are shown as means Â± standard deviations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-fig1-figsupp1-v1.tif"/></fig></fig-group><p>To investigate the potential relationship between SnOCs and the degeneration of spinal endplates in the context of LSI and aging, co-staining of TRAP, a glycosylated monomeric metalloprotein enzyme expressed in osteoclasts, and p16, a tumor suppressor and established marker for cellular senescence, was performed (<xref ref-type="fig" rid="fig1">Figure 1h</xref>). We found that compared to the control young sham mice, there was a significantly increased number of p16<sup>+</sup>TRAP<sup>+</sup> cells in the LSI and aged mice, indicative of SnOCs occurring in the endplates of these two mouse models (<xref ref-type="fig" rid="fig1">Figure 1h and m</xref>). To confirm the occurrence of SnOCs in the endplates in the LSI and aged mice, we stained the adjacent slides with TRAP and senescence-associated beta-galactosidase (SA-Î²Gal) or HMGB1, markers for cellular senescence, respectively, and found that SnOCs existed in the two LBP mouse models but not in the sham controls (<xref ref-type="fig" rid="fig1">Figure 1i, j, n, and o</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1a and b</xref>).</p><p>These findings collectively show a strong association between the presence of SnOCs and the development of spinal hypersensitivity, along with the degenerative changes in the endplates of mice subjected to LSI and during the aging process.</p></sec><sec id="s2-2"><title>ABT263 effectively depletes endplate SnOCs in the LSI and aging mouse models</title><p>To study the contribution of SnOCs to spinal pain, we first needed to show that such cells could be successfully depleted. Thus, we treated 24-month-old aged mice and 3-month-old sham and LSI mice with ABT263, a specific inhibitor targeting the anti-apoptotic proteins BCL-2 and BCL-xL, effectively leading to the depletion of SnOCs (<xref ref-type="bibr" rid="bib9">Chang et al., 2016</xref>). ABT263 was administered via gavage at a dose of 50 mg/kg per day for 7 days per cycle, with two cycles separated by a 2-week interval, resulting in a total treatment period of 4 weeks. Remarkably, after the administration of ABT263, we observed a significant reduction of SnOCs in the endplates compared to the PBS-treated group (<xref ref-type="fig" rid="fig2">Figure 2aâc</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>ABT263 effectively depletes endplate senescent osteoclasts (SnOCs) in the lumbar spine instability (LSI) and aging mouse models.</title><p>(<bold>aâc</bold>) Immunofluorescent staining of p16 (green), tartrate-resistant acid phosphatase (TRAP) (red), and nuclei (4â²,6-diamidino-2-phenylindole [DAPI]; blue) of the endplates in aged (<bold>a</bold>) and LSI mice (<bold>b</bold>) injected with PBS (control) or ABT263 and the quantitative analysis of SnOCs based on dual staining for p16 and TRAP (<bold>c</bold>). nâ¥4 per group. Scale bar, 20 Î¼m. Statistical significance was determined by one-way ANOVA, and all data are shown as means Â± standard deviations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-fig2-v1.tif"/></fig></sec><sec id="s2-3"><title>Eliminating SnOCs reduces spinal hypersensitivity</title><p>To investigate spinal hypersensitivity, pain behavioral tests, including the von Frey test, hot plate test, and active wheel test, were conducted in sham, LSI, and aged mice treated with ABT263 and PBS, respectively. In the aged mice, ABT263 treatment resulted in a significant reduction in PWF (<xref ref-type="fig" rid="fig3">Figure 3a and b</xref>) and prolonged heat response times (<xref ref-type="fig" rid="fig3">Figure 3c</xref>) compared to the PBS-treated mice. In addition, there is a significant increased PWF in aged mice treated with PBS compared with young mice, particularly at 0.4 g instead of 0.07 g (<xref ref-type="fig" rid="fig3">Figure 3a and b</xref>). Furthermore, aged mice treated with PBS exhibited a significant reduction in both distance traveled and active time when compared to young mice (<xref ref-type="fig" rid="fig3">Figure 3d and e</xref>). Additionally, PBS-treated aged mice demonstrated a significantly shortened heat response time relative to young mice (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). Importantly, these aged mice treated with ABT263 exhibited significantly increased distance traveled and active time compared to aged mice that received PBS injections (<xref ref-type="fig" rid="fig3">Figure 3d and e</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>ABT263 treatment improves the symptomatic spinal pain behavior in the aged and lumbar spine instability (LSI) mouse models.</title><p>(<bold>a, b</bold>) The paw withdrawal frequency (PWF) in response to mechanical stimulation (von Frey test, 0. 07 g (<bold>a</bold>) and 0.4 g (<bold>b</bold>)) in aged mice treated with PBS or ABT263 compared to young adult mice. (<bold>câe</bold>) Time (in seconds) spent on a hot plate (<bold>c</bold>), as well as spontaneous activity, including distance traveled (<bold>d</bold>) and active time (<bold>e</bold>), on the wheel within 48 hr in aged mice treated with PBS or ABT263 compared to young adult mice. (<bold>f, g</bold>) The PWF in response to mechanical stimulation (von Frey test, 0. 07 g (<bold>f</bold>) and 0.4 g (<bold>g</bold>)) in the LSI mouse model treated with PBS or ABT263 compared to sham-operated mice. (<bold>hâj</bold>) Time (in seconds) spent on a hot plate (<bold>h</bold>), as well as spontaneous activity analysis, including distance traveled (<bold>i</bold>) and active time (<bold>j</bold>) on the wheel within 48 hr in the sham and LSI mice treated with PBS or ABT263. nâ¥4 per group. Statistical significance was determined by one-way ANOVA, and all data are shown as means Â± standard deviations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-fig3-v1.tif"/></fig><p>Notably, LSI mice treated with ABT263 also demonstrated substantial improvements across several parameters compared to the PBS-treated control mice. These improvements included lower PWF (<xref ref-type="fig" rid="fig3">Figure 3f and g</xref>), prolonged heat response time (<xref ref-type="fig" rid="fig3">Figure 3h</xref>), increased distance traveled (<xref ref-type="fig" rid="fig3">Figure 3i</xref>), and extended active time (<xref ref-type="fig" rid="fig3">Figure 3j</xref>). These results collectively indicate that the elimination of SnOCs reduces spinal hypersensitivity in both aged and LSI mouse models.</p></sec><sec id="s2-4"><title>Depletion of SnOCs reduces spinal degeneration and sustains endplate microarchitecture</title><p>To determine the effect of SnOCs on endplate architecture, degeneration, and osteoclast formation in the context of spinal pain in the aged mice, we conducted Î¼CT analysis and immunostaining in aged mice treated with ABT263, or PBS and untreated 3-month-old young mice (<xref ref-type="fig" rid="fig4">Figure 4aâe</xref>). There was a significant reduction in endplate porosity and Tb.Sp of the caudal endplates of L4/5 in the aged mice treated with ABT263 compared to the PBS-treated aged group (<xref ref-type="fig" rid="fig4">Figure 4f and g</xref>). The PBS-treated aged mice exhibited a significant increase in endplate porosity (<xref ref-type="fig" rid="fig4">Figure 4f</xref>) and Tb.Sp (<xref ref-type="fig" rid="fig4">Figure 4g</xref>) compared to young mice. To examine the effects of ABT263 on endplate degeneration, we performed Safranin O staining and immunofluorescent staining to target matrix metalloproteinase 13-containing (MMP13<sup>+</sup>) and type X collagen-containing (ColX<sup>+</sup>) components within the endplate (<xref ref-type="fig" rid="fig4">Figure 4bâd</xref>). In the aged model, the ABT263-treated group exhibited a significant reduction in endplate score (<xref ref-type="fig" rid="fig4">Figure 4h</xref>), as well as the distribution of MMP13 and ColX within the endplates, compared to aged mice treated with PBS (<xref ref-type="fig" rid="fig4">Figure 4i and j</xref>). PBS-treated aged mice showed a significant elevation in endplate score (<xref ref-type="fig" rid="fig4">Figure 4h</xref>), as well as an increased distribution of MMP13 and ColX within the endplates when compared to young mice (<xref ref-type="fig" rid="fig4">Figure 4i and j</xref>). Furthermore, TRAP staining demonstrated a substantial rise in the count of TRAP<sup>+</sup> osteoclasts within the endplates of aged mice in comparison to young control mice. Importantly, ABT263 treatment resulted in a significant reduction of TRAP<sup>+</sup> osteoclasts within the endplates compared to PBS treatment (<xref ref-type="fig" rid="fig4">Figure 4e and k</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Depletion of senescent osteoclasts (SnOCs) reduces spinal degeneration and sustains endplate microarchitecture in aged mice.</title><p>(<bold>a</bold>) Microcomputed tomography (Î¼CT) images of the aged mouse caudal endplates of L4âL5 injected with PBS or ABT263. Scale bar, 1 mm. (<bold>b</bold>) Representative images of Safranin O and fast green staining of coronal sections of the caudal endplates of L4â5 in aged mice caudal endplates of L4âL5 injected with PBS or ABT263, respectively. Lower panners are zoomed in images from upper white boxes. Scale bar, 1 mm (upper panels) and 100 Î¼m (lower panels). (<bold>c</bold>) Representative images of spine degeneration marker MMP13 (red) and nuclei (4â²,6-diamidino-2-phenylindole [DAPI]; blue) staining in aged mouse caudal endplates of L4âL5 injected with PBS or ABT263. Scale bar, 100 Î¼m. (<bold>d</bold>) Representative images of spine degeneration marker ColX (red) and nuclei (DAPI; blue) staining in aged mouse caudal endplates of L4âL5 injected with PBS or ABT263. Scale bar, 100 Î¼m. (<bold>e</bold>) Representative images of tartrate-resistant acid phosphatase (TRAP) (magenta) staining of coronal sections of the caudal endplates of L4â5 in aged mice caudal endplates of L4âL5 injected with PBS or ABT263, respectively. Lower panners are zoomed-in images from upper white boxes. Scale bar, 100 Î¼m. (<bold>f</bold>) The quantitative analysis of the porosity percentage. (<bold>g</bold>) The quantitative analysis of the trabecular separation. (<bold>h</bold>) The endplate score based on the Safranin O and fast green staining. (<bold>i</bold>) Quantitative analysis of the intensity mean value of MMP13 in endplates per mm2. (<bold>j</bold>) Quantitative analysis of the intensity mean value of ColX in endplates per mm2. (<bold>k</bold>) The quantitative analysis of the number of TRAP-positive cells in the endplate per mm2. nâ¥3 per group. Statistical significance was determined by one-way ANOVA, and all data are shown as means Â± standard deviations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-fig4-v1.tif"/></fig><p>We next conducted Î¼CT analysis and immunostaining in sham and LSI mice treated with ABT263 or PBS (<xref ref-type="fig" rid="fig5">Figure 5aâe</xref>) to determine the effect of SnOCs on endplate architecture, degeneration, and osteoclast formation in the context of spinal pain. In the LSI mice, ABT263 treatment significantly mitigated the porosity and Tb.Sp of the caudal endplates of L4/5 compared to the PBS-treated group (<xref ref-type="fig" rid="fig5">Figure 5a, f, and g</xref>). Safranin O staining and immunofluorescent staining of ColX and MMP13 within the endplate demonstrated ABT263 administration significantly reduced endplate score (<xref ref-type="fig" rid="fig5">Figure 5b and h</xref>), the distribution of MMP13 (<xref ref-type="fig" rid="fig5">Figure 5c and i</xref>) and ColX (<xref ref-type="fig" rid="fig5">Figure 5d and j</xref>) and TRAP<sup>+</sup> osteoclasts (<xref ref-type="fig" rid="fig5">Figure 5e and k</xref>) in the endplates compared to LSI mice treated with PBS. These findings collectively suggest the pivotal role of ABT263 in mitigating spinal degeneration and maintaining endplate remodeling in the context of spine pain.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Depletion of senescent osteoclasts (SnOCs) reduces spinal degeneration and sustains endplate microarchitecture in lumbar spine instability (LSI) mice.</title><p>(<bold>a</bold>) Microcomputed tomography (Î¼CT) images of adult sham mice and 3-month-old LSI model mice caudal endplates of L4âL5 injected with PBS or ABT263. Scale bar, 1 mm. (<bold>b</bold>) Representative images of Safranin O and fast green staining in different groups. Lower panners are zoomed-in images from upper white boxes. Scale bar, 1 mm (upper panels) and 100 Î¼m (lower panels). (<bold>c</bold>) Representative images of immunofluorescent staining of spine degeneration marker MMP13 (red) and nuclei (4â²,6-diamidino-2-phenylindole [DAPI]; blue). Scale bar, 100 Î¼m. (<bold>d</bold>) Representative images of immunofluorescent staining of spine degeneration marker ColX (red) and nuclei (DAPI; blue). Scale bar, 100 Î¼m. (<bold>e</bold>) Representative images of tartrate-resistant acid phosphatase (TRAP) (magenta) staining in different groups. Lower panners are zoomed-in images from upper white boxes. Scale bar, 100 Î¼m. (<bold>f</bold>) The quantitative analysis of the porosity percentage of the mouse caudal endplates of L4â5 measured by the Î¼CT. (<bold>g</bold>) The quantitative analysis of the trabecular separation (Tb.Sp) of the mouse caudal endplates of L4â5 measured by the Î¼CT. (<bold>h</bold>) The endplate score based on the Safranin O and fast green staining. (<bold>i</bold>) Quantitative analysis of the intensity mean value of MMP13 in endplates per mm2. (<bold>j</bold>) Quantitative analysis of the intensity mean value of ColX in endplates per mm2. (<bold>k</bold>) The quantitative analysis of the number of TRAP-positive cells in the endplate per mm2. nâ¥3 per group. Statistical significance was determined by one-way ANOVA, and all data are shown as means Â± standard deviations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-fig5-v1.tif"/></fig></sec><sec id="s2-5"><title>Depletion of SnOCs abrogates sensory innervation and pain</title><p>We previously found that sensory innervation occurs in the porous endplates, contributing to spinal hypersensitivity, in LSI and aged mice (<xref ref-type="bibr" rid="bib48">Ni et al., 2019</xref>). To evaluate the contribution of SnOCs to sensory innervation and pain in LSI and aged mice, we co-stained for calcitonin gene-related peptide (CGRP), a marker of peptidergic nociceptive C nerve fibers, and PGP9.5, a broad marker of nerve fibers, in the endplates of LSI and aged mice treated with ABT263 or PBS (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). Notably, we found fewer CGRP<sup>+</sup> PGP9.5<sup>+</sup> nerves in LSI mice and aged mice treated with ABT263 compared to those treated with PBS (<xref ref-type="fig" rid="fig6">Figure 6bâe</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Depletion of senescent osteoclasts (SnOCs) abrogates sensory innervation and pain in aged and lumbar spine instability (LSI) mouse models.</title><p>(<bold>a</bold>) Representative images of immunofluorescent analysis of calcitonin gene-related peptide (CGRP) (green), PGP9.5 (red), and nuclei (4â²,6-diamidino-2-phenylindole [DAPI]; blue) of adult sham, LSI, and aged mice injected with PBS or ABT263. Scale bar, 20 Î¼m. (<bold>b</bold>) Quantitative analysis of the intensity mean value of PGP9.5 per mm2 in aged mice. (<bold>c</bold>) Quantitative analysis of the intensity mean value of CGRP per mm2 in aged mice. (<bold>d</bold>) Quantitative analysis of the intensity mean value of PGP9.5 per mm2 in the LSI mouse model. (<bold>e</bold>) Quantitative analysis of the intensity mean value of CGRP per mm2 in the LSI mouse model. (<bold>f, g</bold>) Relative fold expression of <italic>Ntn</italic> and <italic>Ngf</italic> in aged mice (<bold>f</bold>) or LSI mice (<bold>g</bold>) with or without ABT263 treatment. nâ¥4 per group. Statistical significance in panels b, c, and f are analyzed using t-tests, while panels d, e, and g are subjected to one-way ANOVA. All data are shown as means Â± standard deviations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 1.</label><caption><title>ELISA analysis of Netrin-1 and NGF in L3â5 endplates of sham, LSI+PBS, and LSI+ABT263 mice.</title><p>(<bold>a</bold>) Enzyme-linked immunosorbent assay (ELISA) analysis showing the concentration of Netrin-1 in L3â5 endplates of adult sham, lumbar spine instability (LSI) + PBS, and LSI + ABT263 mice. (<bold>b</bold>) ELISA analysis showing the concentration of NGF in L3â5 endplates of adult sham, LSI + PBS, and LSI + ABT263 mice. n=3 per group. Statistical significance was determined by one-way ANOVA, and all data are shown as means Â± standard deviations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-fig6-figsupp1-v1.tif"/></fig></fig-group><p>To investigate the mechanisms underlying sensory innervation-induced spinal pain, we performed RT-qPCR to screen for expression of mediators regulating nerve fiber innervation and outgrowth, including Netrin-1 and NGF (<xref ref-type="bibr" rid="bib7">Bian et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Papadakis et al., 2011</xref>; <xref ref-type="bibr" rid="bib51">Rodriguez et al., 2012</xref>). Compared to the young sham mice, aging and LSI was associated with significantly increased expression of <italic>Ntn</italic> and <italic>Ngf</italic> (the genes encoding netrin-1 and Ngf, respectively), which was substantially attenuated by ABT263 treatment in both LSI and aged mice (<xref ref-type="fig" rid="fig6">Figure 6f and g</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1a, b</xref>).</p><p>Our earlier data showed that CGRP<sup>+</sup> nociceptive nerve fibers and blood vessels were increased in the cavities of sclerotic endplates in the LSI and aged mice (<xref ref-type="bibr" rid="bib48">Ni et al., 2019</xref>). To study whether elimination of SnOCs prevent such blood vessel growth into the endplates, we co-stained for CD31, an angiogenesis marker (green), and Emcn, an endothelial cells marker (red), in the endplates of sham, LSI, and aged mice treated with PBS or ABT263 (<xref ref-type="fig" rid="fig7">Figure 7a</xref>). In conjunction with the sensory nerve distribution within the porous endplates, we found noticeable growth of CD31<sup>+</sup>Emcn<sup>+</sup> blood vessels into the endplates of the LSI and aged mice compared to young sham mice. This observation points toward an ongoing process of active ossification in the endplate. ABT263 treatment in the LSI and aged mouse models significantly mitigated the aberrant innervation of sensory nerves and blood vessels within the endplate compared to the PBS-treated mice (<xref ref-type="fig" rid="fig7">Figure 7bâe</xref>). Collectively, these findings underscore that ABT263 treatment effectively reduces spinal hypersensitivity by diminishing the innervation of sensory nerves and blood vessels within the endplate.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Depletion of senescent osteoclasts (SnOCs) abrogates blood vessels innervation in aged and lumbar spine instability (LSI) mouse models.</title><p>(<bold>a</bold>) Representative images of immunofluorescent analysis of CD31, an angiogenesis marker (green), Emcn, an endothelial cell marker (red) and nuclei (4â²,6-diamidino-2-phenylindole [DAPI]; blue) of adult sham, LSI, and aged mice injected with PBS or ABT263. Scale bar, 20 Î¼m. (<bold>b</bold>) Quantitative analysis of the intensity mean value of CD31 per mm2 in sham, LSI mice treated with PBS or ABT263. (<bold>c</bold>) Quantitative analysis of the intensity mean value of CD31 per mm2 in aged mice treated with PBS or ABT263. (<bold>d</bold>) Quantitative analysis of the intensity mean value of Emcn per mm2 in sham, LSI mice treated with PBS or ABT263. (<bold>e</bold>) Quantitative analysis of the intensity mean value of Emcn per mm2 in aged mice treated with PBS or ABT263. nâ¥4 per group. Statistical significance was determined by one-way ANOVA, and all data are shown as means Â± standard deviations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>LBP affects individuals of all ages and is a leading contributor to disease burden worldwide. Despite advancements in its assessment and treatment, the management of LBP remains a challenge for researchers and clinicians alike. Defects in a number of anatomical structures within the back may be responsible for back pain, including the intervertebral discs, facet joints, muscles, ligaments, and nerve root sheaths. Of these, the intervertebral discs, facet joints, and sacroiliac joints are implicated in the majority of the cases of LBP (<xref ref-type="bibr" rid="bib31">Kallewaard et al., 2010</xref>). Furthermore, more than one structure may be contributing to the pain at any one time. During healing, neovascularization occurs and minute sensory nerves can penetrate the disrupted annulus and nucleus pulposus, leading to mechanical and chemical sensitization (<xref ref-type="bibr" rid="bib61">Zhen et al., 2022</xref>).</p><p>During LSI or aging, endplates undergo ossification, leading to elevated osteoclast activity and increased porosity (<xref ref-type="bibr" rid="bib6">Bian et al., 2016</xref>; <xref ref-type="bibr" rid="bib7">Bian et al., 2017</xref>; <xref ref-type="bibr" rid="bib49">Papadakis et al., 2011</xref>; <xref ref-type="bibr" rid="bib51">Rodriguez et al., 2012</xref>). The progressive porous transformation of endplates, accompanied by a narrowed IVD space, is a hallmark of spinal degeneration (<xref ref-type="bibr" rid="bib51">Rodriguez et al., 2012</xref>; <xref ref-type="bibr" rid="bib56">Taher et al., 2012</xref>). Considering that pain arises from nociceptors, it is plausible that LBP may be attributed to sensory innervation within endplates. Additionally, porous endplates exhibit higher nerve density compared to normal endplates or degenerative nucleus pulposus (<xref ref-type="bibr" rid="bib20">Fields et al., 2014</xref>). Netrin-1, a crucial axon guidance factor facilitating nerve protrusion, has been implicated in this process (<xref ref-type="bibr" rid="bib24">Hand and Kolodkin, 2017</xref>; <xref ref-type="bibr" rid="bib45">Moore et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Serafini et al., 1996</xref>). The receptor mediating Netrin-1-induced neuronal sprouting, deleted in colorectal cancer (DCC), was found to co-localize with CGRP<sup>+</sup> sensory nerve fibers in endplates after LSI surgery (<xref ref-type="bibr" rid="bib21">Forcet et al., 2002</xref>; <xref ref-type="bibr" rid="bib55">Shu et al., 2000</xref>). In summary, during LSI or aging, osteoclastic lineage cells secrete Netrin-1, inducing extrusion and innervation of CGRP<sup>+</sup> sensory nerve fibers within the spaces created by osteoclast resorption. This Netrin-1/DCC-mediated pain signal is subsequently transmitted to the dorsal root ganglion (DRG) or higher brain levels. In our previous study, we found that osteoclasts induce sensory innervation of the porous areas of sclerotic endplates, which induced spinal hypersensitivity in LSI-injured mice and in aging. Inhibition of osteoclast formation by knockout of <italic>Rankl</italic> in the osteocytes significantly inhibits LSI-induced porosity of endplates, sensory innervation, and spinal hypersensitivity (<xref ref-type="bibr" rid="bib48">Ni et al., 2019</xref>). Likewise, knockout of <italic>Ntn1</italic> in osteoclasts abrogates sensory innervation into porous endplates and spinal hypersensitivity (<xref ref-type="bibr" rid="bib48">Ni et al., 2019</xref>). In an OA mouse model, we found a role for osteoclast-secreted netrin-1 in the induction of sensory nerve axonal growth in the subchondral bone. Reduction of osteoclast formation by knockout of <italic>Rankl</italic> in osteocytes inhibited the growth of sensory nerves into subchondral bone, DRG neuron hyperexcitability, and behavioral measures of pain hypersensitivity (<xref ref-type="bibr" rid="bib62">Zhu et al., 2019</xref>). Our previous study revealed that osteoclast-lineage cells may promote both nerve and vessel growth in osteoarthritic subchondral bone, leading to disease progression and pain (<xref ref-type="bibr" rid="bib59">Xie et al., 2014</xref>). Here, we report that SnOCs are mainly responsible for modulating the secretion of netrin-1 and NGF, which mediate sensory innervation and induce hypersensitivity of spine.</p><p>Osteoclasts are the principal bone-resorbing cells essential for bone remodeling and skeletal development. Here, we report that osteoclasts in the endplate of the vertebral column undergo cellular senescence during injury and aging. The senescence process is programmed by a conserved mechanism because it is restricted to a specific region and follows a specific time course. Cellular senescence was defined by the presence of a senescence marker, SA-Î²Gal, and a key senescence mediator, p16INK4a, detected in the bone tissue sections. In the present study, we found that the number of TRAP<sup>+</sup> and SA-Î²Gal<sup>+</sup> or p16<sup>+</sup> senescent osteoclasts in endplates was significantly increased in LSI-injured mice and aged mice compared to sham-injured mice with PBS treatment. These findings support our hypothesis that increased numbers of SnOCs in LSI or aging conditions contribute to nerve innervation factors secretion, which leads to spine pain.</p><p>Current LBP management strategies have limited therapeutic effects, and progressive pathological spinal changes are observed frequently with these treatments. According to the American College of Physicians guidelines, pharmacological recommendations for acute or subacute LBP should begin with NSAIDs or muscle relaxants (moderate-quality evidence). There is no consensus on the duration of NSAID use, and caution is advised with persistent use due to concerns for cardiovascular and gastrointestinal adverse events. Guidelines by the American College of Physicians (<xref ref-type="bibr" rid="bib50">Qaseem et al., 2017</xref>) recommend tramadol or duloxetine as a second-line treatment and opioids as the last-line treatment for chronic LBP. A meta-analysis showed that opioids offer only modest, short-term pain relief in patients with chronic LBP (<xref ref-type="bibr" rid="bib1">Abdel Shaheed et al., 2016</xref>). The addictive potential of opioids coupled with several side effects limits their use in the management of such pain (<xref ref-type="bibr" rid="bib50">Qaseem et al., 2017</xref>). Consequently, these drugs provide insufficient and unsustained pain relief with considerable adverse effects.</p><p>A clinical study demonstrated that nerve density is higher in porous endplates than in normal endplates and is associated with pain. Radiofrequency denervation treatment can be used for pain relief originating from the lumbar facet joints (<xref ref-type="bibr" rid="bib35">Lee et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Maas et al., 2015</xref>). However, National Institute for Health and Care Excellence (NICE) guidelines from the United Kingdom (<xref ref-type="bibr" rid="bib5">Bernstein et al., 2017</xref>) recommend considering radiofrequency denervation only when the main source of pain originates from the facet joints, when pain is moderate to severe, and only when evidence-based multidisciplinary treatment has failed. During LBP progression, sensory nerves and blood vessels are aberrantly innervated in the endplate, which leads to pain. In this study, we aimed to reduce pain by decreasing nerve innervation. We found that SnOCs mediate nerve fiber innervation by elevated secretion of netrin-1 and NGF. Moreover, our previous study reported that osteoclasts can secret netrin-1 to attract sensory nerve growth (<xref ref-type="bibr" rid="bib48">Ni et al., 2019</xref>). NGF can be produced by osteoblasts in response to mechanical load (<xref ref-type="bibr" rid="bib32">Kamei et al., 2022</xref>) or by bone marrow stromal cells (BMSCs), and Sema3A is secreted by osteoblasts (<xref ref-type="bibr" rid="bib57">Tomlinson et al., 2017</xref>). We believe a cross-talk exists between osteoclasts and osteoblasts or BMSCs after LSI or aging to modulate the secretion of nerve fiber innervation mediators.</p><p>The recent discovery that senescent cells play a causative role in aging and in many age-related diseases suggests that cellular senescence is a fundamental mechanism of aging. In aging, as well as in metabolic disorders, the immune response is affected by senescent cells that no longer replicate, but have a senescence-associated secretory phenotype that produces high levels of proinflammatory molecules. Certain chemotherapy drugs, known as senolytics, however, kill senescent cells and other drugs, called anti-SASP drugs, block their proinflammatory cell signaling. ABT263 is a selective BCL-2 and BCL-xL inhibitor and is one of the most potent and broad-spectrum senolytic drugs. In the current study, we explored the role of ABT263 to manage spinal pain, and we found to it could effectively clear SnOCs cells in two mouse models. A decreased number of SnOCs will relieve pain by decreasing sensory neuron innervation in the endplate. However, ABT263 does not specifically eliminate SnOCs and thus further studies are required to prove the role of SnOCs in spinal hypersensitivity. Furthermore, ABT263 usually possesses various on-target and/or off-target toxicities, which could preclude its clinical use. Even so, for the first time to the best of our knowledge, we show evidence that SnOCs promote LBP by neurotrophic-mediated pathways. Our findings suggest that depletion of SnOCs, perhaps by use of a senolytic, can reduce sensory innervation and attenuate LBP, thus representing a new avenue in the management of this widespread condition (<xref ref-type="fig" rid="fig8">Figure 8</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Schematic diagram of senescent osteoclasts (SnOCs) in porous endplate-induced spinal pain.</title><p>In lumbar spine instability (LSI) or aging mouse models there is an induction of spinal hypersensitivity due to increased numbers of SnOCs in the endplate, leading to excessive secretion of sensory nerve mediators, such as Netrin-1, to attract calcitonin gene-related peptide (CGRP<sup>+</sup>) sensory nerve innervation. Additionally, aberrant microarchitecture and spinal degeneration are associated with increased wiring of sensory nerve fibers and H-type vessels in the endplate, all further contributing to lower back pain.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-fig8-v1.tif"/></fig></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Mice</title><p>Three- and 24-month-old C57BL/6J male mice were purchased from Jackson Laboratory. Three-month-old mice were anesthetized with ketamine (Ketalar, 0.13 mg/kg, intraperitoneally) and xylazine (Millipore Sigma; PHR3264, 12 mg/kg, intraperitoneally). Then, the L3âL5 spinous processes, and the supraspinous and interspinous ligaments were resected to induce instability of the lumbar spine and to create the LSI model (<xref ref-type="bibr" rid="bib6">Bian et al., 2016</xref>; <xref ref-type="bibr" rid="bib3">Ariga et al., 2001</xref>; <xref ref-type="bibr" rid="bib43">Miyamoto et al., 1991</xref>). For mice in the sham group, we only surgically detached the posterior paravertebral muscles from L3 to L5. ABT263 (Navitoclax, Selleckchem, S1001) was administered to mice by gavage at 50 mg/kg per day for 7 days per cycle for two cycles with a 2-week interval between the cycles (the whole treatment time was 4 weeks). ABT263 was administered to aged (24 M) C57BL/6J mice (12 per group) at the age of 23 months. In the meantime, 4-month-old C57BL/6J mice 4 weeks post LSI or sham operation were treated with ABT263 or vehicle (PBS) (<xref ref-type="bibr" rid="bib9">Chang et al., 2016</xref>). The control group (sham group) for the LSI group refers to C57BL/6J mice that did not undergo LSI surgery, while the control group (young group) for the aged group refers to 4-month-old C57BL/6J mice. All mice were maintained at the animal facility of The Johns Hopkins University School of Medicine (protocol number: MO21M276, MO21M270, MO22M18). All experimental protocols were approved by the Animal Care and Use Committee of The Johns Hopkins University, Baltimore, MD, USA.</p></sec><sec id="s4-2"><title>Behavioral testing</title><p>Behavioral tests were performed after ABT263 administration and before sacrifice. All behavioral tests were performed by the same investigator, who was blinded to the study groups.</p><p>The hind PWF in response to a mechanical stimulus was determined using von Frey filaments of 0.07 g and 0.4 g (Aesthesio Precision Tactile Sensory Evaluator). Mice were placed on a wire metal mesh grid covered with a clear plastic cage. Acclimatization of the animals in the enclosure was for 30 min. We applied von Frey filaments to the mid-plantar surface of the hind paw through the mesh floor with enough pressure to buckle the filaments. A trial consisted of 10 times at 1 s intervals. Mechanical withdrawal frequency was calculated as the number of withdrawal times in response to 10 applications after three replicates.</p><p>The Hargreaves test of nociception threshold was evaluated by the Model Heated 400 Base. The animals were transferred from the holding room to the enclosure and acclimatization of the animals in the enclosure was for 30 min. The duration of exposure before the hind paw withdrawn with three replicates is recorded after focusing the mouseâs mid-plantar surface of the hind paw with the light.</p><p>Spontaneous wheel-running activity was recorded using activity wheels designed for mice (model BIO-ACTIVW-M, Bioseb) (<xref ref-type="bibr" rid="bib15">Cobos et al., 2012</xref>). The software enabled recording of activity in a cage similar to the miceâs home cage, with the wheel spun in both directions. The device was connected to an analyzer that automatically recorded the spontaneous activity. We evaluated the distance traveled, maximum speed, and total active time during 2 days for each mouse.</p></sec><sec id="s4-3"><title>RT-qPCR</title><p>Mice were euthanized with an overdose of isoflurane inhalation. Total RNA was then extracted from the L4âL5 lumbar spine endplate tissue samples. Briefly, spine endplate tissue was ground in liquid nitrogen and isolated from Buffer RLT Plus using RNeasy Plus Mini Kits (QIAGEN, Germany) and homogenized directly with ultrasound (probe sonication at 50 Hz for three times, 10 s per cycle). The purity of RNA was measured by the absorbance at 260/280 nm. Then, the RNA was reverse transcribed into complementary DNA by PrimeScript RT (reverse transcriptase) using a primeScript RT-PCR kit (Takara), and qPCR was performed with SYBR Green-Master Mix (Thermo Fisher Scientific, USA) on a QuantStudio 3 (Applied Biosystems, USA). Relative expression was calculated for each gene by the 2-â³â³CT method, with glyceraldehyde 3-phosphate dehydrogenase (<italic>GAPDH</italic>) used for normalization. Primers used for RT-qPCR are listed below: <italic>Netrin-1</italic>: forward: 5â- <named-content content-type="sequence">CCTGTCACCTCTGCAACTCT</named-content> -3â, reverse: 5â- <named-content content-type="sequence">TGTGCGGGTTATTGAGGTCG</named-content> -3â; <italic>NGF</italic>: forward: 5â- <named-content content-type="sequence">CTGGCCACACTGAGGTGCAT</named-content> -3â, reverse: 5â-<named-content content-type="sequence">TCCTGCAGGGACATTGCTCTC</named-content>-3â; <italic>BDNF</italic>: forward:5â- TGCAGGGGC <named-content content-type="sequence">ATAGACAAAAGG</named-content> -3â, reverse: 5â- <named-content content-type="sequence">CTTATGAATCGCCAGCCAATTCTC</named-content> -3â; <italic>NT3</italic>: forward: 5â- <named-content content-type="sequence">CTCATTATCAAGTTGATCCA</named-content> -3â, reverse: 5â- <named-content content-type="sequence">CCTCCGTGGTGATGTTCTATT</named-content> â3â; <italic>Slit3</italic>: forward: 5â- AGT <named-content content-type="sequence">TGTCTGCCTTCCGACAG</named-content> -3â, reverse: 5â- <named-content content-type="sequence">TTTCCATGGAGG</named-content> GTCAGCAC -3â; <italic>GAPDH</italic>: forward: 5'-<named-content content-type="sequence">ATGTGTCCGTCGTGGATCTGA</named-content>-3', reverse: 5'-<named-content content-type="sequence">ATGCCTGCTTCACCACCTTCTT</named-content>-3'.</p></sec><sec id="s4-4"><title>ELISA</title><p>We determined the concentration of Netrin-1 (LSBio, LS-F5882) and NGF (Boster, EK0470) in the L3âL5 endplates using the ELISA Development Kit according to the manufacturerâs instructions.</p></sec><sec id="s4-5"><title>Î¼CT</title><p>Mice were euthanized with an overdose of isoflurane inhalation and flushed with PBS for 5 min followed by 10% buffered formalin perfusion for 5 min via the left ventricle. Then, the whole lumbar spine was dissected and fixed in 10% buffered formalin for 48 hr, transferred into PBS, and examined by high-resolution Î¼CT (Skyscan1172). The scanner was set at a voltage of 55âkV, a current of 181âÎ¼A, and a resolution of 9.0 Î¼m per pixel to measure the endplates and vertebrae. The ribs on the lower thoracic spine were included for identification of L4âL5 unit localization. Images were reconstructed and analyzed using NRecon v1.6 and CTAn v1.9 (Skyscan US, San Jose, CA, USA), respectively. Coronal images of the L4âL5 unit were used to perform three-dimensional histomorphometric analyses of the caudal endplate. The three-dimensional structural parameters analyzed were total porosity and trabecular bone separation distribution (Tb.Sp) for the endplates. Six consecutive coronal-oriented images were used for showing three-dimensional reconstruction of the endplates and the vertebrae using three-dimensional model visualization software, CTVol v2.0 (Skyscan US).</p></sec><sec id="s4-6"><title>Histochemistry, immunohistochemistry, and histomorphometry</title><p>After Î¼CT scanning, the spine samples were decalcified in 0.5 M EDTA (pH 7.4) for 30 days and embedded in paraffin or optimal cutting temperature compound (Sakura Finetek, Torrance, CA, USA).</p><p>Four-Î¼m-thick coronal-oriented sections of the L4âL5 lumbar spine were processed for Safranin O (Sigma-Aldrich, S2255) and fast green (Sigma-Aldrich, F7252) staining, TRAP (Sigma-Aldrich, 387A-1KT) staining, and immunohistochemistry staining with an established protocol (<xref ref-type="bibr" rid="bib48">Ni et al., 2019</xref>). Thirty-Î¼m-thick coronal-oriented sections were prepared for blood vessel-related immunofluorescent staining, and 10-Âµm-thick coronal-oriented sections were used for other immunofluorescent staining.</p><p>The sections were incubated with primary antibodies to mouse Col X (1:100, ab260040, Abcam), MMP13 (1:100, ab219620, Abcam), Endomucin (1:100, sc-65495, Santa Cruz Biotechnology), CD31 (1:100, 550389, BD Biosciences), CGRP (1:100, ab81887, Abcam), PGP9.5 (1:100, SAB4503057, Sigma-Aldrich), Netrin-1 (1:100, ab39370, Abcam), TRAP (1:100, PA5-116970, Invitrogen), overnight at 4Â°C. Then, the corresponding secondary antibodies and 4â²,6-diamidino-2-phenylindole (Vector, H-1200) were added onto the sections for 1 hr while avoiding light.</p><p>The sample images were observed and captured by the confocal microscope (Zeiss LSM 780). ImageJ (NIH) software was used for quantitative analysis. We calculated endplate scores as described previously (<xref ref-type="bibr" rid="bib8">Boos et al., 2002</xref>; <xref ref-type="bibr" rid="bib42">Masuda et al., 2005</xref>).</p></sec><sec id="s4-7"><title>Statistics</title><p>All data analyses were performed using SPSS, version 15.0, software (IBM Corp.). Data are presented as means Â±âstandard deviations. Unpaired, two-tailed Studentâs t-tests were used for comparisons between two groups. One-way ANOVA with Bonferroniâs post hoc test was used for comparisons among multiple groups. For all experiments, p&lt;0.05 was considered to be significant. There were no samples or animals that were excluded from the analysis. The experiments were randomized, and the investigators were blinded to allocation during experiments and outcome assessment.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Reviewing editor, <italic>eLife</italic></p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Validation</p></fn><fn fn-type="con" id="con5"><p>Conceptualization</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Supervision</p></fn><fn fn-type="con" id="con7"><p>Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All mice were maintained at the animal facility of The Johns Hopkins University School of Medicine (protocol number: MO21M276, MO21M270, MO22M18). All experimental protocols were approved by the Animal Care and Use Committee of The Johns Hopkins University, Baltimore, MD. All surgery was performed under ketamine and xylazine anesthesia, and every effort was made to minimize suffering.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-92889-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and Mendeley Data (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17632/m4hhfk3tw7.1">https://doi.org/10.17632/m4hhfk3tw7.1</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17632/m4hhfk3tw7.2">https://doi.org/10.17632/m4hhfk3tw7.2</ext-link>).</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Benkato</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Senescence of endplate osteoclasts induces sensory innervation and spinal pain</data-title><source>Mendeley Data</source><pub-id pub-id-type="doi">10.17632/m4hhfk3tw7.1</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Benkato</surname><given-names>K</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Senescence of endplate osteoclasts induces sensory innervation and spinal pain</data-title><source>Mendeley Data</source><pub-id pub-id-type="doi">10.17632/m4hhfk3tw7.2</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This research was supported by the United States NIH National Institute on Aging under award numbers R01AG068997, P01AG066603, R01AG076783, R01AR071432 (to XC).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel Shaheed</surname><given-names>C</given-names></name><name><surname>Maher</surname><given-names>CG</given-names></name><name><surname>Williams</surname><given-names>KA</given-names></name><name><surname>Day</surname><given-names>R</given-names></name><name><surname>McLachlan</surname><given-names>AJE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: A systematic review and meta-analysis</article-title><source>JAMA Internal Medicine</source><volume>176</volume><fpage>958</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2016.1251</pub-id><pub-id pub-id-type="pmid">27213267</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>EB</given-names></name><name><surname>Gilsenan</surname><given-names>AW</given-names></name><name><surname>Midkiff</surname><given-names>K</given-names></name><name><surname>Sherrill</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Mann</surname><given-names>BH</given-names></name><name><surname>Masica</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years</article-title><source>Journal of Bone and Mineral Research</source><volume>27</volume><fpage>2429</fpage><lpage>2437</lpage><pub-id pub-id-type="doi">10.1002/jbmr.1768</pub-id><pub-id pub-id-type="pmid">22991313</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariga</surname><given-names>K</given-names></name><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Nakase</surname><given-names>T</given-names></name><name><surname>Okuda</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Yonenobu</surname><given-names>K</given-names></name><name><surname>Yoshikawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The relationship between apoptosis of endplate chondrocytes and aging and degeneration of the intervertebral disc</article-title><source>Spine</source><volume>26</volume><fpage>2414</fpage><lpage>2420</lpage><pub-id pub-id-type="doi">10.1097/00007632-200111150-00004</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>DJ</given-names></name><name><surname>Childs</surname><given-names>BG</given-names></name><name><surname>Durik</surname><given-names>M</given-names></name><name><surname>Wijers</surname><given-names>ME</given-names></name><name><surname>Sieben</surname><given-names>CJ</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Saltness</surname><given-names>RA</given-names></name><name><surname>Jeganathan</surname><given-names>KB</given-names></name><name><surname>Verzosa</surname><given-names>GC</given-names></name><name><surname>Pezeshki</surname><given-names>A</given-names></name><name><surname>Khazaie</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>JD</given-names></name><name><surname>van Deursen</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan</article-title><source>Nature</source><volume>530</volume><fpage>184</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1038/nature16932</pub-id><pub-id pub-id-type="pmid">26840489</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>IA</given-names></name><name><surname>Malik</surname><given-names>Q</given-names></name><name><surname>Carville</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Low back pain and sciatica: summary of NICE guidance</article-title><source>BMJ</source><volume>356</volume><elocation-id>i6748</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.i6748</pub-id><pub-id pub-id-type="pmid">28062522</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bian</surname><given-names>Q</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Kebaish</surname><given-names>K</given-names></name><name><surname>Crane</surname><given-names>JL</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Riley</surname><given-names>LH</given-names></name><name><surname>Sponseller</surname><given-names>PD</given-names></name><name><surname>Guo</surname><given-names>XE</given-names></name><name><surname>Lu</surname><given-names>WW</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Excessive Activation of TGFÎ² by Spinal Instability Causes Vertebral Endplate Sclerosis</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>27093</elocation-id><pub-id pub-id-type="doi">10.1038/srep27093</pub-id><pub-id pub-id-type="pmid">27256073</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bian</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Crane</surname><given-names>JL</given-names></name><name><surname>Kebaish</surname><given-names>K</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Edward Guo</surname><given-names>X</given-names></name><name><surname>Sponseller</surname><given-names>PD</given-names></name><name><surname>SÃ©guin</surname><given-names>CA</given-names></name><name><surname>Riley</surname><given-names>LH</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mechanosignaling activation of TGFÎ² maintains intervertebral disc homeostasis</article-title><source>Bone Research</source><volume>5</volume><elocation-id>17008</elocation-id><pub-id pub-id-type="doi">10.1038/boneres.2017.8</pub-id><pub-id pub-id-type="pmid">28392965</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boos</surname><given-names>N</given-names></name><name><surname>Weissbach</surname><given-names>S</given-names></name><name><surname>Rohrbach</surname><given-names>H</given-names></name><name><surname>Weiler</surname><given-names>C</given-names></name><name><surname>Spratt</surname><given-names>KF</given-names></name><name><surname>Nerlich</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Classification of age-related changes in lumbar intervertebral discs: 2002 Volvo Award in basic science</article-title><source>Spine</source><volume>27</volume><fpage>2631</fpage><lpage>2644</lpage><pub-id pub-id-type="doi">10.1097/00007632-200212010-00002</pub-id><pub-id pub-id-type="pmid">12461389</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shao</surname><given-names>L</given-names></name><name><surname>Laberge</surname><given-names>R-M</given-names></name><name><surname>Demaria</surname><given-names>M</given-names></name><name><surname>Campisi</surname><given-names>J</given-names></name><name><surname>Janakiraman</surname><given-names>K</given-names></name><name><surname>Sharpless</surname><given-names>NE</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Aykin-Burns</surname><given-names>N</given-names></name><name><surname>Krager</surname><given-names>K</given-names></name><name><surname>Ponnappan</surname><given-names>U</given-names></name><name><surname>Hauer-Jensen</surname><given-names>M</given-names></name><name><surname>Meng</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice</article-title><source>Nature Medicine</source><volume>22</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1038/nm.4010</pub-id><pub-id pub-id-type="pmid">26657143</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Mo</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Cheung</surname><given-names>WH</given-names></name><name><surname>Fu</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Effect of Teriparatide on pain relief, and quality of life in postmenopausal females with osteoporotic vertebral compression fractures, a retrospective cohort study</article-title><source>Annals of Palliative Medicine</source><volume>10</volume><fpage>4000</fpage><lpage>4007</lpage><pub-id pub-id-type="doi">10.21037/apm-20-2333</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Shao</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Global, regional and national burden of low back pain 1990-2019: A systematic analysis of the Global Burden of Disease study 2019</article-title><source>Journal of Orthopaedic Translation</source><volume>32</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.jot.2021.07.005</pub-id><pub-id pub-id-type="pmid">34934626</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherif</surname><given-names>H</given-names></name><name><surname>Bisson</surname><given-names>DG</given-names></name><name><surname>Mannarino</surname><given-names>M</given-names></name><name><surname>Rabau</surname><given-names>O</given-names></name><name><surname>Ouellet</surname><given-names>JA</given-names></name><name><surname>Haglund</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Senotherapeutic drugs for human intervertebral disc degeneration and low back pain</article-title><source>eLife</source><volume>9</volume><elocation-id>e54693</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.54693</pub-id><pub-id pub-id-type="pmid">32821059</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Childs</surname><given-names>BG</given-names></name><name><surname>Baker</surname><given-names>DJ</given-names></name><name><surname>Wijshake</surname><given-names>T</given-names></name><name><surname>Conover</surname><given-names>CA</given-names></name><name><surname>Campisi</surname><given-names>J</given-names></name><name><surname>van Deursen</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Senescent intimal foam cells are deleterious at all stages of atherosclerosis</article-title><source>Science</source><volume>354</volume><fpage>472</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1126/science.aaf6659</pub-id><pub-id pub-id-type="pmid">27789842</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>R</given-names></name><name><surname>Qaseem</surname><given-names>A</given-names></name><name><surname>Snow</surname><given-names>V</given-names></name><name><surname>Casey</surname><given-names>D</given-names></name><name><surname>Cross</surname><given-names>JT</given-names></name><name><surname>Shekelle</surname><given-names>P</given-names></name><name><surname>Owens</surname><given-names>DK</given-names></name><collab>Clinical Efficacy Assessment Subcommittee of the American College of Physicians</collab><collab>American College of Physicians</collab><collab>American Pain Society Low Back Pain Guidelines Panel</collab></person-group><year iso-8601-date="2007">2007</year><article-title>Diagnosis and treatment of low back pain: A joint clinical practice guideline from the American College of Physicians and the American Pain Society</article-title><source>Annals of Internal Medicine</source><volume>147</volume><fpage>478</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-147-7-200710020-00006</pub-id><pub-id pub-id-type="pmid">17909209</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cobos</surname><given-names>EJ</given-names></name><name><surname>Ghasemlou</surname><given-names>N</given-names></name><name><surname>Araldi</surname><given-names>D</given-names></name><name><surname>Segal</surname><given-names>D</given-names></name><name><surname>Duong</surname><given-names>K</given-names></name><name><surname>Woolf</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inflammation-induced decrease in voluntary wheel running in mice: a nonreflexive test for evaluating inflammatory pain and analgesia</article-title><source>Pain</source><volume>153</volume><fpage>876</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2012.01.016</pub-id><pub-id pub-id-type="pmid">22341563</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deyo</surname><given-names>RA</given-names></name><name><surname>Cherkin</surname><given-names>D</given-names></name><name><surname>Conrad</surname><given-names>D</given-names></name><name><surname>Volinn</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Cost, controversy, crisis: low back pain and the health of the public</article-title><source>Annual Review of Public Health</source><volume>12</volume><fpage>141</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1146/annurev.pu.12.050191.001041</pub-id><pub-id pub-id-type="pmid">1828670</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deyo</surname><given-names>RA</given-names></name><name><surname>Von Korff</surname><given-names>M</given-names></name><name><surname>Duhrkoop</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Opioids for low back pain</article-title><source>BMJ</source><volume>350</volume><elocation-id>g6380</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.g6380</pub-id><pub-id pub-id-type="pmid">25561513</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Micco</surname><given-names>R</given-names></name><name><surname>Krizhanovsky</surname><given-names>V</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>dâAdda di Fagagna</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cellular senescence in ageing: from mechanisms to therapeutic opportunities</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>22</volume><fpage>75</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-00314-w</pub-id><pub-id pub-id-type="pmid">33328614</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farr</surname><given-names>JN</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Weivoda</surname><given-names>MM</given-names></name><name><surname>Monroe</surname><given-names>DG</given-names></name><name><surname>Fraser</surname><given-names>DG</given-names></name><name><surname>Onken</surname><given-names>JL</given-names></name><name><surname>Negley</surname><given-names>BA</given-names></name><name><surname>Sfeir</surname><given-names>JG</given-names></name><name><surname>Ogrodnik</surname><given-names>MB</given-names></name><name><surname>Hachfeld</surname><given-names>CM</given-names></name><name><surname>LeBrasseur</surname><given-names>NK</given-names></name><name><surname>Drake</surname><given-names>MT</given-names></name><name><surname>Pignolo</surname><given-names>RJ</given-names></name><name><surname>Pirtskhalava</surname><given-names>T</given-names></name><name><surname>Tchkonia</surname><given-names>T</given-names></name><name><surname>Oursler</surname><given-names>MJ</given-names></name><name><surname>Kirkland</surname><given-names>JL</given-names></name><name><surname>Khosla</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Targeting cellular senescence prevents age-related bone loss in mice</article-title><source>Nature Medicine</source><volume>23</volume><fpage>1072</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1038/nm.4385</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fields</surname><given-names>AJ</given-names></name><name><surname>Liebenberg</surname><given-names>EC</given-names></name><name><surname>Lotz</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Innervation of pathologies in the lumbar vertebral end plate and intervertebral disc</article-title><source>The Spine Journal</source><volume>14</volume><fpage>513</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.spinee.2013.06.075</pub-id><pub-id pub-id-type="pmid">24139753</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forcet</surname><given-names>C</given-names></name><name><surname>Stein</surname><given-names>E</given-names></name><name><surname>Pays</surname><given-names>L</given-names></name><name><surname>Corset</surname><given-names>V</given-names></name><name><surname>Llambi</surname><given-names>F</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent MAPK activation</article-title><source>Nature</source><volume>417</volume><fpage>443</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/nature748</pub-id><pub-id pub-id-type="pmid">11986622</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>H</given-names></name><name><surname>Firtch</surname><given-names>W</given-names></name><name><surname>Tyburski</surname><given-names>M</given-names></name><name><surname>Pressman</surname><given-names>A</given-names></name><name><surname>Ackerson</surname><given-names>L</given-names></name><name><surname>Hamilton</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>W</given-names></name><name><surname>Carver</surname><given-names>R</given-names></name><name><surname>Maratukulam</surname><given-names>A</given-names></name><name><surname>Won</surname><given-names>LA</given-names></name><name><surname>Carragee</surname><given-names>E</given-names></name><name><surname>Avins</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Oral steroids for acute radiculopathy due to a herniated lumbar disk: a randomized clinical trial</article-title><source>JAMA</source><volume>313</volume><fpage>1915</fpage><lpage>1923</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.4468</pub-id><pub-id pub-id-type="pmid">25988461</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorissen</surname><given-names>B</given-names></name><name><surname>de Bruin</surname><given-names>A</given-names></name><name><surname>Miranda-Bedate</surname><given-names>A</given-names></name><name><surname>Korthagen</surname><given-names>N</given-names></name><name><surname>Wolschrijn</surname><given-names>C</given-names></name><name><surname>de Vries</surname><given-names>TJ</given-names></name><name><surname>van Weeren</surname><given-names>R</given-names></name><name><surname>Tryfonidou</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hypoxia negatively affects senescence in osteoclasts and delays osteoclastogenesis</article-title><source>Journal of Cellular Physiology</source><volume>234</volume><fpage>414</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1002/jcp.26511</pub-id><pub-id pub-id-type="pmid">29932209</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hand</surname><given-names>RA</given-names></name><name><surname>Kolodkin</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Netrin-Mediated Axon Guidance to the CNS Midline Revisited</article-title><source>Neuron</source><volume>94</volume><fpage>691</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2017.05.012</pub-id><pub-id pub-id-type="pmid">28521119</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>KD</given-names></name><name><surname>Krege</surname><given-names>JH</given-names></name><name><surname>Marcus</surname><given-names>R</given-names></name><name><surname>Mitlak</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Osteosarcoma and teriparatide?</article-title><source>Journal of Bone and Mineral Research</source><volume>22</volume><elocation-id>334</elocation-id><pub-id pub-id-type="doi">10.1359/jbmr.061111</pub-id><pub-id pub-id-type="pmid">17129179</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartvigsen</surname><given-names>J</given-names></name><name><surname>Hancock</surname><given-names>MJ</given-names></name><name><surname>Kongsted</surname><given-names>A</given-names></name><name><surname>Louw</surname><given-names>Q</given-names></name><name><surname>Ferreira</surname><given-names>ML</given-names></name><name><surname>Genevay</surname><given-names>S</given-names></name><name><surname>Hoy</surname><given-names>D</given-names></name><name><surname>Karppinen</surname><given-names>J</given-names></name><name><surname>Pransky</surname><given-names>G</given-names></name><name><surname>Sieper</surname><given-names>J</given-names></name><name><surname>Smeets</surname><given-names>RJ</given-names></name><name><surname>Underwood</surname><given-names>M</given-names></name><collab>Lancet Low Back Pain Series Working Group</collab></person-group><year iso-8601-date="2018">2018</year><article-title>What low back pain is and why we need to pay attention</article-title><source>Lancet</source><volume>391</volume><fpage>2356</fpage><lpage>2367</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)30480-X</pub-id><pub-id pub-id-type="pmid">29573870</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>S</given-names></name><name><surname>Sharpless</surname><given-names>NE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Senescence in health and disease</article-title><source>Cell</source><volume>169</volume><fpage>1000</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.015</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoy</surname><given-names>D</given-names></name><name><surname>Bain</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>G</given-names></name><name><surname>March</surname><given-names>L</given-names></name><name><surname>Brooks</surname><given-names>P</given-names></name><name><surname>Blyth</surname><given-names>F</given-names></name><name><surname>Woolf</surname><given-names>A</given-names></name><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Buchbinder</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A systematic review of the global prevalence of low back pain</article-title><source>Arthritis and Rheumatism</source><volume>64</volume><fpage>2028</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1002/art.34347</pub-id><pub-id pub-id-type="pmid">22231424</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>SL</given-names></name><name><surname>Abate</surname><given-names>D</given-names></name><name><surname>Abate</surname><given-names>KH</given-names></name><name><surname>Abay</surname><given-names>SM</given-names></name><name><surname>Abbafati</surname><given-names>C</given-names></name><name><surname>Abbasi</surname><given-names>N</given-names></name><name><surname>Abbastabar</surname><given-names>H</given-names></name><name><surname>Abd-Allah</surname><given-names>F</given-names></name><name><surname>Abdela</surname><given-names>J</given-names></name><name><surname>Abdelalim</surname><given-names>A</given-names></name><name><surname>Abdollahpour</surname><given-names>I</given-names></name><name><surname>Abdulkader</surname><given-names>RS</given-names></name><name><surname>Abebe</surname><given-names>Z</given-names></name><name><surname>Abera</surname><given-names>SF</given-names></name><name><surname>Abil</surname><given-names>OZ</given-names></name><name><surname>Abraha</surname><given-names>HN</given-names></name><name><surname>Abu-Raddad</surname><given-names>LJ</given-names></name><name><surname>Abu-Rmeileh</surname><given-names>NME</given-names></name><name><surname>Accrombessi</surname><given-names>MMK</given-names></name><name><surname>Acharya</surname><given-names>D</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name><name><surname>Ackerman</surname><given-names>IN</given-names></name><name><surname>Adamu</surname><given-names>AA</given-names></name><name><surname>Adebayo</surname><given-names>OM</given-names></name><name><surname>Adekanmbi</surname><given-names>V</given-names></name><name><surname>Adetokunboh</surname><given-names>OO</given-names></name><name><surname>Adib</surname><given-names>MG</given-names></name><name><surname>Adsuar</surname><given-names>JC</given-names></name><name><surname>Afanvi</surname><given-names>KA</given-names></name><name><surname>Afarideh</surname><given-names>M</given-names></name><name><surname>Afshin</surname><given-names>A</given-names></name><name><surname>Agarwal</surname><given-names>G</given-names></name><name><surname>Agesa</surname><given-names>KM</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Aghayan</surname><given-names>SA</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Ahmadi</surname><given-names>A</given-names></name><name><surname>Ahmadi</surname><given-names>M</given-names></name><name><surname>Ahmadieh</surname><given-names>H</given-names></name><name><surname>Ahmed</surname><given-names>MB</given-names></name><name><surname>Aichour</surname><given-names>AN</given-names></name><name><surname>Aichour</surname><given-names>I</given-names></name><name><surname>Aichour</surname><given-names>MTE</given-names></name><name><surname>Akinyemiju</surname><given-names>T</given-names></name><name><surname>Akseer</surname><given-names>N</given-names></name><name><surname>Al-Aly</surname><given-names>Z</given-names></name><name><surname>Al-Eyadhy</surname><given-names>A</given-names></name><name><surname>Al-Mekhlafi</surname><given-names>HM</given-names></name><name><surname>Al-Raddadi</surname><given-names>RM</given-names></name><name><surname>Alahdab</surname><given-names>F</given-names></name><name><surname>Alam</surname><given-names>K</given-names></name><name><surname>Alam</surname><given-names>T</given-names></name><name><surname>Alashi</surname><given-names>A</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Alene</surname><given-names>KA</given-names></name><name><surname>Alijanzadeh</surname><given-names>M</given-names></name><name><surname>Alizadeh-Navaei</surname><given-names>R</given-names></name><name><surname>Aljunid</surname><given-names>SM</given-names></name><name><surname>Alkerwi</surname><given-names>A</given-names></name><name><surname>Alla</surname><given-names>F</given-names></name><name><surname>Allebeck</surname><given-names>P</given-names></name><name><surname>Alouani</surname><given-names>MML</given-names></name><name><surname>Altirkawi</surname><given-names>K</given-names></name><name><surname>Alvis-Guzman</surname><given-names>N</given-names></name><name><surname>Amare</surname><given-names>AT</given-names></name><name><surname>Aminde</surname><given-names>LN</given-names></name><name><surname>Ammar</surname><given-names>W</given-names></name><name><surname>Amoako</surname><given-names>YA</given-names></name><name><surname>Anber</surname><given-names>NH</given-names></name><name><surname>Andrei</surname><given-names>CL</given-names></name><name><surname>Androudi</surname><given-names>S</given-names></name><name><surname>Animut</surname><given-names>MD</given-names></name><name><surname>Anjomshoa</surname><given-names>M</given-names></name><name><surname>Ansha</surname><given-names>MG</given-names></name><name><surname>Antonio</surname><given-names>CAT</given-names></name><name><surname>Anwari</surname><given-names>P</given-names></name><name><surname>Arabloo</surname><given-names>J</given-names></name><name><surname>Arauz</surname><given-names>A</given-names></name><name><surname>Aremu</surname><given-names>O</given-names></name><name><surname>Ariani</surname><given-names>F</given-names></name><name><surname>Armoon</surname><given-names>B</given-names></name><name><surname>ÃrnlÃ¶v</surname><given-names>J</given-names></name><name><surname>Arora</surname><given-names>A</given-names></name><name><surname>Artaman</surname><given-names>A</given-names></name><name><surname>Aryal</surname><given-names>KK</given-names></name><name><surname>Asayesh</surname><given-names>H</given-names></name><name><surname>Asghar</surname><given-names>RJ</given-names></name><name><surname>Ataro</surname><given-names>Z</given-names></name><name><surname>Atre</surname><given-names>SR</given-names></name><name><surname>Ausloos</surname><given-names>M</given-names></name><name><surname>Avila-Burgos</surname><given-names>L</given-names></name><name><surname>Avokpaho</surname><given-names>EFGA</given-names></name><name><surname>Awasthi</surname><given-names>A</given-names></name><name><surname>Ayala Quintanilla</surname><given-names>BP</given-names></name><name><surname>Ayer</surname><given-names>R</given-names></name><name><surname>Azzopardi</surname><given-names>PS</given-names></name><name><surname>Babazadeh</surname><given-names>A</given-names></name><name><surname>Badali</surname><given-names>H</given-names></name><name><surname>Badawi</surname><given-names>A</given-names></name><name><surname>Bali</surname><given-names>AG</given-names></name><name><surname>Ballesteros</surname><given-names>KE</given-names></name><name><surname>Ballew</surname><given-names>SH</given-names></name><name><surname>Banach</surname><given-names>M</given-names></name><name><surname>Banoub</surname><given-names>JAM</given-names></name><name><surname>Banstola</surname><given-names>A</given-names></name><name><surname>Barac</surname><given-names>A</given-names></name><name><surname>Barboza</surname><given-names>MA</given-names></name><name><surname>Barker-Collo</surname><given-names>SL</given-names></name><name><surname>BÃ¤rnighausen</surname><given-names>TW</given-names></name><name><surname>Barrero</surname><given-names>LH</given-names></name><name><surname>Baune</surname><given-names>BT</given-names></name><name><surname>Bazargan-Hejazi</surname><given-names>S</given-names></name><name><surname>Bedi</surname><given-names>N</given-names></name><name><surname>Beghi</surname><given-names>E</given-names></name><name><surname>Behzadifar</surname><given-names>M</given-names></name><name><surname>Behzadifar</surname><given-names>M</given-names></name><name><surname>BÃ©jot</surname><given-names>Y</given-names></name><name><surname>Belachew</surname><given-names>AB</given-names></name><name><surname>Belay</surname><given-names>YA</given-names></name><name><surname>Bell</surname><given-names>ML</given-names></name><name><surname>Bello</surname><given-names>AK</given-names></name><name><surname>Bensenor</surname><given-names>IM</given-names></name><name><surname>Bernabe</surname><given-names>E</given-names></name><name><surname>Bernstein</surname><given-names>RS</given-names></name><name><surname>Beuran</surname><given-names>M</given-names></name><name><surname>Beyranvand</surname><given-names>T</given-names></name><name><surname>Bhala</surname><given-names>N</given-names></name><name><surname>Bhattarai</surname><given-names>S</given-names></name><name><surname>Bhaumik</surname><given-names>S</given-names></name><name><surname>Bhutta</surname><given-names>ZA</given-names></name><name><surname>Biadgo</surname><given-names>B</given-names></name><name><surname>Bijani</surname><given-names>A</given-names></name><name><surname>Bikbov</surname><given-names>B</given-names></name><name><surname>Bilano</surname><given-names>V</given-names></name><name><surname>Bililign</surname><given-names>N</given-names></name><name><surname>Bin Sayeed</surname><given-names>MS</given-names></name><name><surname>Bisanzio</surname><given-names>D</given-names></name><name><surname>Blacker</surname><given-names>BF</given-names></name><name><surname>Blyth</surname><given-names>FM</given-names></name><name><surname>Bou-Orm</surname><given-names>IR</given-names></name><name><surname>Boufous</surname><given-names>S</given-names></name><name><surname>Bourne</surname><given-names>R</given-names></name><name><surname>Brady</surname><given-names>OJ</given-names></name><name><surname>Brainin</surname><given-names>M</given-names></name><name><surname>Brant</surname><given-names>LC</given-names></name><name><surname>Brazinova</surname><given-names>A</given-names></name><name><surname>Breitborde</surname><given-names>NJK</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Briant</surname><given-names>PS</given-names></name><name><surname>Briggs</surname><given-names>AM</given-names></name><name><surname>Briko</surname><given-names>AN</given-names></name><name><surname>Britton</surname><given-names>G</given-names></name><name><surname>Brugha</surname><given-names>T</given-names></name><name><surname>Buchbinder</surname><given-names>R</given-names></name><name><surname>Busse</surname><given-names>R</given-names></name><name><surname>Butt</surname><given-names>ZA</given-names></name><name><surname>Cahuana-Hurtado</surname><given-names>L</given-names></name><name><surname>Cano</surname><given-names>J</given-names></name><name><surname>CÃ¡rdenas</surname><given-names>R</given-names></name><name><surname>Carrero</surname><given-names>JJ</given-names></name><name><surname>Carter</surname><given-names>A</given-names></name><name><surname>Carvalho</surname><given-names>F</given-names></name><name><surname>CastaÃ±eda-Orjuela</surname><given-names>CA</given-names></name><name><surname>Castillo Rivas</surname><given-names>J</given-names></name><name><surname>Castro</surname><given-names>F</given-names></name><name><surname>CatalÃ¡-LÃ³pez</surname><given-names>F</given-names></name><name><surname>Cercy</surname><given-names>KM</given-names></name><name><surname>Cerin</surname><given-names>E</given-names></name><name><surname>Chaiah</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>AR</given-names></name><name><surname>Chang</surname><given-names>H-Y</given-names></name><name><surname>Chang</surname><given-names>J-C</given-names></name><name><surname>Charlson</surname><given-names>FJ</given-names></name><name><surname>Chattopadhyay</surname><given-names>A</given-names></name><name><surname>Chattu</surname><given-names>VK</given-names></name><name><surname>Chaturvedi</surname><given-names>P</given-names></name><name><surname>Chiang</surname><given-names>PP-C</given-names></name><name><surname>Chin</surname><given-names>KL</given-names></name><name><surname>Chitheer</surname><given-names>A</given-names></name><name><surname>Choi</surname><given-names>J-YJ</given-names></name><name><surname>Chowdhury</surname><given-names>R</given-names></name><name><surname>Christensen</surname><given-names>H</given-names></name><name><surname>Christopher</surname><given-names>DJ</given-names></name><name><surname>Cicuttini</surname><given-names>FM</given-names></name><name><surname>Ciobanu</surname><given-names>LG</given-names></name><name><surname>Cirillo</surname><given-names>M</given-names></name><name><surname>Claro</surname><given-names>RM</given-names></name><name><surname>Collado-Mateo</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Cortesi</surname><given-names>PA</given-names></name><name><surname>Cortinovis</surname><given-names>M</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Cousin</surname><given-names>E</given-names></name><name><surname>Criqui</surname><given-names>MH</given-names></name><name><surname>Cromwell</surname><given-names>EA</given-names></name><name><surname>Cross</surname><given-names>M</given-names></name><name><surname>Crump</surname><given-names>JA</given-names></name><name><surname>Dadi</surname><given-names>AF</given-names></name><name><surname>Dandona</surname><given-names>L</given-names></name><name><surname>Dandona</surname><given-names>R</given-names></name><name><surname>Dargan</surname><given-names>PI</given-names></name><name><surname>Daryani</surname><given-names>A</given-names></name><name><surname>Das Gupta</surname><given-names>R</given-names></name><name><surname>Das Neves</surname><given-names>J</given-names></name><name><surname>Dasa</surname><given-names>TT</given-names></name><name><surname>Davey</surname><given-names>G</given-names></name><name><surname>Davis</surname><given-names>AC</given-names></name><name><surname>Davitoiu</surname><given-names>DV</given-names></name><name><surname>De Courten</surname><given-names>B</given-names></name><name><surname>De La Hoz</surname><given-names>FP</given-names></name><name><surname>De Leo</surname><given-names>D</given-names></name><name><surname>De Neve</surname><given-names>J-W</given-names></name><name><surname>Degefa</surname><given-names>MG</given-names></name><name><surname>Degenhardt</surname><given-names>L</given-names></name><name><surname>Deiparine</surname><given-names>S</given-names></name><name><surname>Dellavalle</surname><given-names>RP</given-names></name><name><surname>Demoz</surname><given-names>GT</given-names></name><name><surname>Deribe</surname><given-names>K</given-names></name><name><surname>Dervenis</surname><given-names>N</given-names></name><name><surname>Des Jarlais</surname><given-names>DC</given-names></name><name><surname>Dessie</surname><given-names>GA</given-names></name><name><surname>Dey</surname><given-names>S</given-names></name><name><surname>Dharmaratne</surname><given-names>SD</given-names></name><name><surname>Dinberu</surname><given-names>MT</given-names></name><name><surname>Dirac</surname><given-names>MA</given-names></name><name><surname>Djalalinia</surname><given-names>S</given-names></name><name><surname>Doan</surname><given-names>L</given-names></name><name><surname>Dokova</surname><given-names>K</given-names></name><name><surname>Doku</surname><given-names>DT</given-names></name><name><surname>Dorsey</surname><given-names>ER</given-names></name><name><surname>Doyle</surname><given-names>KE</given-names></name><name><surname>Driscoll</surname><given-names>TR</given-names></name><name><surname>Dubey</surname><given-names>M</given-names></name><name><surname>Dubljanin</surname><given-names>E</given-names></name><name><surname>Duken</surname><given-names>EE</given-names></name><name><surname>Duncan</surname><given-names>BB</given-names></name><name><surname>Duraes</surname><given-names>AR</given-names></name><name><surname>Ebrahimi</surname><given-names>H</given-names></name><name><surname>Ebrahimpour</surname><given-names>S</given-names></name><name><surname>Echko</surname><given-names>MM</given-names></name><name><surname>Edvardsson</surname><given-names>D</given-names></name><name><surname>Effiong</surname><given-names>A</given-names></name><name><surname>Ehrlich</surname><given-names>JR</given-names></name><name><surname>El Bcheraoui</surname><given-names>C</given-names></name><name><surname>El Sayed Zaki</surname><given-names>M</given-names></name><name><surname>El-Khatib</surname><given-names>Z</given-names></name><name><surname>Elkout</surname><given-names>H</given-names></name><name><surname>Elyazar</surname><given-names>IRF</given-names></name><name><surname>Enayati</surname><given-names>A</given-names></name><name><surname>Endries</surname><given-names>AY</given-names></name><name><surname>Er</surname><given-names>B</given-names></name><name><surname>Erskine</surname><given-names>HE</given-names></name><name><surname>Eshrati</surname><given-names>B</given-names></name><name><surname>Eskandarieh</surname><given-names>S</given-names></name><name><surname>Esteghamati</surname><given-names>A</given-names></name><name><surname>Esteghamati</surname><given-names>S</given-names></name><name><surname>Fakhim</surname><given-names>H</given-names></name><name><surname>Fallah Omrani</surname><given-names>V</given-names></name><name><surname>Faramarzi</surname><given-names>M</given-names></name><name><surname>Fareed</surname><given-names>M</given-names></name><name><surname>Farhadi</surname><given-names>F</given-names></name><name><surname>Farid</surname><given-names>TA</given-names></name><name><surname>Farinha</surname><given-names>CSE</given-names></name><name><surname>Farioli</surname><given-names>A</given-names></name><name><surname>Faro</surname><given-names>A</given-names></name><name><surname>Farvid</surname><given-names>MS</given-names></name><name><surname>Farzadfar</surname><given-names>F</given-names></name><name><surname>Feigin</surname><given-names>VL</given-names></name><name><surname>Fentahun</surname><given-names>N</given-names></name><name><surname>Fereshtehnejad</surname><given-names>S-M</given-names></name><name><surname>Fernandes</surname><given-names>E</given-names></name><name><surname>Fernandes</surname><given-names>JC</given-names></name><name><surname>Ferrari</surname><given-names>AJ</given-names></name><name><surname>Feyissa</surname><given-names>GT</given-names></name><name><surname>Filip</surname><given-names>I</given-names></name><name><surname>Fischer</surname><given-names>F</given-names></name><name><surname>Fitzmaurice</surname><given-names>C</given-names></name><name><surname>Foigt</surname><given-names>NA</given-names></name><name><surname>Foreman</surname><given-names>KJ</given-names></name><name><surname>Fox</surname><given-names>J</given-names></name><name><surname>Frank</surname><given-names>TD</given-names></name><name><surname>Fukumoto</surname><given-names>T</given-names></name><name><surname>Fullman</surname><given-names>N</given-names></name><name><surname>FÃ¼rst</surname><given-names>T</given-names></name><name><surname>Furtado</surname><given-names>JM</given-names></name><name><surname>Futran</surname><given-names>ND</given-names></name><name><surname>Gall</surname><given-names>S</given-names></name><name><surname>Ganji</surname><given-names>M</given-names></name><name><surname>Gankpe</surname><given-names>FG</given-names></name><name><surname>Garcia-Basteiro</surname><given-names>AL</given-names></name><name><surname>Gardner</surname><given-names>WM</given-names></name><name><surname>Gebre</surname><given-names>AK</given-names></name><name><surname>Gebremedhin</surname><given-names>AT</given-names></name><name><surname>Gebremichael</surname><given-names>TG</given-names></name><name><surname>Gelano</surname><given-names>TF</given-names></name><name><surname>Geleijnse</surname><given-names>JM</given-names></name><name><surname>Genova-Maleras</surname><given-names>R</given-names></name><name><surname>Geramo</surname><given-names>YCD</given-names></name><name><surname>Gething</surname><given-names>PW</given-names></name><name><surname>Gezae</surname><given-names>KE</given-names></name><name><surname>Ghadiri</surname><given-names>K</given-names></name><name><surname>Ghasemi Falavarjani</surname><given-names>K</given-names></name><name><surname>Ghasemi-Kasman</surname><given-names>M</given-names></name><name><surname>Ghimire</surname><given-names>M</given-names></name><name><surname>Ghosh</surname><given-names>R</given-names></name><name><surname>Ghoshal</surname><given-names>AG</given-names></name><name><surname>Giampaoli</surname><given-names>S</given-names></name><name><surname>Gill</surname><given-names>PS</given-names></name><name><surname>Gill</surname><given-names>TK</given-names></name><name><surname>Ginawi</surname><given-names>IA</given-names></name><name><surname>Giussani</surname><given-names>G</given-names></name><name><surname>Gnedovskaya</surname><given-names>EV</given-names></name><name><surname>Goldberg</surname><given-names>EM</given-names></name><name><surname>Goli</surname><given-names>S</given-names></name><name><surname>GÃ³mez-DantÃ©s</surname><given-names>H</given-names></name><name><surname>Gona</surname><given-names>PN</given-names></name><name><surname>Gopalani</surname><given-names>SV</given-names></name><name><surname>Gorman</surname><given-names>TM</given-names></name><name><surname>Goulart</surname><given-names>AC</given-names></name><name><surname>Goulart</surname><given-names>BNG</given-names></name><name><surname>Grada</surname><given-names>A</given-names></name><name><surname>Grams</surname><given-names>ME</given-names></name><name><surname>Grosso</surname><given-names>G</given-names></name><name><surname>Gugnani</surname><given-names>HC</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Gupta</surname><given-names>PC</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>T</given-names></name><name><surname>Gyawali</surname><given-names>B</given-names></name><name><surname>Haagsma</surname><given-names>JA</given-names></name><name><surname>Hachinski</surname><given-names>V</given-names></name><name><surname>Hafezi-Nejad</surname><given-names>N</given-names></name><name><surname>Haghparast Bidgoli</surname><given-names>H</given-names></name><name><surname>Hagos</surname><given-names>TB</given-names></name><name><surname>Hailu</surname><given-names>GB</given-names></name><name><surname>Haj-Mirzaian</surname><given-names>A</given-names></name><name><surname>Haj-Mirzaian</surname><given-names>A</given-names></name><name><surname>Hamadeh</surname><given-names>RR</given-names></name><name><surname>Hamidi</surname><given-names>S</given-names></name><name><surname>Handal</surname><given-names>AJ</given-names></name><name><surname>Hankey</surname><given-names>GJ</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Harb</surname><given-names>HL</given-names></name><name><surname>Harikrishnan</surname><given-names>S</given-names></name><name><surname>Haro</surname><given-names>JM</given-names></name><name><surname>Hasan</surname><given-names>M</given-names></name><name><surname>Hassankhani</surname><given-names>H</given-names></name><name><surname>Hassen</surname><given-names>HY</given-names></name><name><surname>Havmoeller</surname><given-names>R</given-names></name><name><surname>Hawley</surname><given-names>CN</given-names></name><name><surname>Hay</surname><given-names>RJ</given-names></name><name><surname>Hay</surname><given-names>SI</given-names></name><name><surname>Hedayatizadeh-Omran</surname><given-names>A</given-names></name><name><surname>Heibati</surname><given-names>B</given-names></name><name><surname>Hendrie</surname><given-names>D</given-names></name><name><surname>Henok</surname><given-names>A</given-names></name><name><surname>Herteliu</surname><given-names>C</given-names></name><name><surname>Heydarpour</surname><given-names>S</given-names></name><name><surname>Hibstu</surname><given-names>DT</given-names></name><name><surname>Hoang</surname><given-names>HT</given-names></name><name><surname>Hoek</surname><given-names>HW</given-names></name><name><surname>Hoffman</surname><given-names>HJ</given-names></name><name><surname>Hole</surname><given-names>MK</given-names></name><name><surname>Homaie Rad</surname><given-names>E</given-names></name><name><surname>Hoogar</surname><given-names>P</given-names></name><name><surname>Hosgood</surname><given-names>HD</given-names></name><name><surname>Hosseini</surname><given-names>SM</given-names></name><name><surname>Hosseinzadeh</surname><given-names>M</given-names></name><name><surname>Hostiuc</surname><given-names>M</given-names></name><name><surname>Hostiuc</surname><given-names>S</given-names></name><name><surname>Hotez</surname><given-names>PJ</given-names></name><name><surname>Hoy</surname><given-names>DG</given-names></name><name><surname>Hsairi</surname><given-names>M</given-names></name><name><surname>Htet</surname><given-names>AS</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>JJ</given-names></name><name><surname>Huynh</surname><given-names>CK</given-names></name><name><surname>Iburg</surname><given-names>KM</given-names></name><name><surname>Ikeda</surname><given-names>CT</given-names></name><name><surname>Ileanu</surname><given-names>B</given-names></name><name><surname>Ilesanmi</surname><given-names>OS</given-names></name><name><surname>Iqbal</surname><given-names>U</given-names></name><name><surname>Irvani</surname><given-names>SSN</given-names></name><name><surname>Irvine</surname><given-names>CMS</given-names></name><name><surname>Islam</surname><given-names>SMS</given-names></name><name><surname>Islami</surname><given-names>F</given-names></name><name><surname>Jacobsen</surname><given-names>KH</given-names></name><name><surname>Jahangiry</surname><given-names>L</given-names></name><name><surname>Jahanmehr</surname><given-names>N</given-names></name><name><surname>Jain</surname><given-names>SK</given-names></name><name><surname>Jakovljevic</surname><given-names>M</given-names></name><name><surname>Javanbakht</surname><given-names>M</given-names></name><name><surname>Jayatilleke</surname><given-names>AU</given-names></name><name><surname>Jeemon</surname><given-names>P</given-names></name><name><surname>Jha</surname><given-names>RP</given-names></name><name><surname>Jha</surname><given-names>V</given-names></name><name><surname>Ji</surname><given-names>JS</given-names></name><name><surname>Johnson</surname><given-names>CO</given-names></name><name><surname>Jonas</surname><given-names>JB</given-names></name><name><surname>Jozwiak</surname><given-names>JJ</given-names></name><name><surname>Jungari</surname><given-names>SB</given-names></name><name><surname>JÃ¼risson</surname><given-names>M</given-names></name><name><surname>Kabir</surname><given-names>Z</given-names></name><name><surname>Kadel</surname><given-names>R</given-names></name><name><surname>Kahsay</surname><given-names>A</given-names></name><name><surname>Kalani</surname><given-names>R</given-names></name><name><surname>Kanchan</surname><given-names>T</given-names></name><name><surname>Karami</surname><given-names>M</given-names></name><name><surname>Karami Matin</surname><given-names>B</given-names></name><name><surname>Karch</surname><given-names>A</given-names></name><name><surname>Karema</surname><given-names>C</given-names></name><name><surname>Karimi</surname><given-names>N</given-names></name><name><surname>Karimi</surname><given-names>SM</given-names></name><name><surname>Kasaeian</surname><given-names>A</given-names></name><name><surname>Kassa</surname><given-names>DH</given-names></name><name><surname>Kassa</surname><given-names>GM</given-names></name><name><surname>Kassa</surname><given-names>TD</given-names></name><name><surname>Kassebaum</surname><given-names>NJ</given-names></name><name><surname>Katikireddi</surname><given-names>SV</given-names></name><name><surname>Kawakami</surname><given-names>N</given-names></name><name><surname>Karyani</surname><given-names>AK</given-names></name><name><surname>Keighobadi</surname><given-names>MM</given-names></name><name><surname>Keiyoro</surname><given-names>PN</given-names></name><name><surname>Kemmer</surname><given-names>L</given-names></name><name><surname>Kemp</surname><given-names>GR</given-names></name><name><surname>Kengne</surname><given-names>AP</given-names></name><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Khader</surname><given-names>YS</given-names></name><name><surname>Khafaei</surname><given-names>B</given-names></name><name><surname>Khafaie</surname><given-names>MA</given-names></name><name><surname>Khajavi</surname><given-names>A</given-names></name><name><surname>Khalil</surname><given-names>IA</given-names></name><name><surname>Khan</surname><given-names>EA</given-names></name><name><surname>Khan</surname><given-names>MS</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Khang</surname><given-names>Y-H</given-names></name><name><surname>Khazaei</surname><given-names>M</given-names></name><name><surname>Khoja</surname><given-names>AT</given-names></name><name><surname>Khosravi</surname><given-names>A</given-names></name><name><surname>Khosravi</surname><given-names>MH</given-names></name><name><surname>Kiadaliri</surname><given-names>AA</given-names></name><name><surname>Kiirithio</surname><given-names>DN</given-names></name><name><surname>Kim</surname><given-names>C-I</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>Y-E</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kimokoti</surname><given-names>RW</given-names></name><name><surname>Kinfu</surname><given-names>Y</given-names></name><name><surname>Kisa</surname><given-names>A</given-names></name><name><surname>Kissimova-Skarbek</surname><given-names>K</given-names></name><name><surname>KivimÃ¤ki</surname><given-names>M</given-names></name><name><surname>Knudsen</surname><given-names>AKS</given-names></name><name><surname>Kocarnik</surname><given-names>JM</given-names></name><name><surname>Kochhar</surname><given-names>S</given-names></name><name><surname>Kokubo</surname><given-names>Y</given-names></name><name><surname>Kolola</surname><given-names>T</given-names></name><name><surname>Kopec</surname><given-names>JA</given-names></name><name><surname>Kosen</surname><given-names>S</given-names></name><name><surname>Kotsakis</surname><given-names>GA</given-names></name><name><surname>Koul</surname><given-names>PA</given-names></name><name><surname>Koyanagi</surname><given-names>A</given-names></name><name><surname>Kravchenko</surname><given-names>MA</given-names></name><name><surname>Krishan</surname><given-names>K</given-names></name><name><surname>Krohn</surname><given-names>KJ</given-names></name><name><surname>Kuate Defo</surname><given-names>B</given-names></name><name><surname>Kucuk Bicer</surname><given-names>B</given-names></name><name><surname>Kumar</surname><given-names>GA</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Kyu</surname><given-names>HH</given-names></name><name><surname>Lad</surname><given-names>DP</given-names></name><name><surname>Lad</surname><given-names>SD</given-names></name><name><surname>Lafranconi</surname><given-names>A</given-names></name><name><surname>Lalloo</surname><given-names>R</given-names></name><name><surname>Lallukka</surname><given-names>T</given-names></name><name><surname>Lami</surname><given-names>FH</given-names></name><name><surname>Lansingh</surname><given-names>VC</given-names></name><name><surname>Latifi</surname><given-names>A</given-names></name><name><surname>Lau</surname><given-names>KM-M</given-names></name><name><surname>Lazarus</surname><given-names>JV</given-names></name><name><surname>Leasher</surname><given-names>JL</given-names></name><name><surname>Ledesma</surname><given-names>JR</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><name><surname>Leigh</surname><given-names>J</given-names></name><name><surname>Leung</surname><given-names>J</given-names></name><name><surname>Levi</surname><given-names>M</given-names></name><name><surname>Lewycka</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Liben</surname><given-names>ML</given-names></name><name><surname>Lim</surname><given-names>L-L</given-names></name><name><surname>Lim</surname><given-names>SS</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Lodha</surname><given-names>R</given-names></name><name><surname>Looker</surname><given-names>KJ</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name><name><surname>Lorkowski</surname><given-names>S</given-names></name><name><surname>Lotufo</surname><given-names>PA</given-names></name><name><surname>Low</surname><given-names>N</given-names></name><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Lucas</surname><given-names>TCD</given-names></name><name><surname>Lucchesi</surname><given-names>LR</given-names></name><name><surname>Lunevicius</surname><given-names>R</given-names></name><name><surname>Lyons</surname><given-names>RA</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Macarayan</surname><given-names>ERK</given-names></name><name><surname>Mackay</surname><given-names>MT</given-names></name><name><surname>Madotto</surname><given-names>F</given-names></name><name><surname>Magdy Abd El Razek</surname><given-names>H</given-names></name><name><surname>Magdy Abd El Razek</surname><given-names>M</given-names></name><name><surname>Maghavani</surname><given-names>DP</given-names></name><name><surname>Mahotra</surname><given-names>NB</given-names></name><name><surname>Mai</surname><given-names>HT</given-names></name><name><surname>Majdan</surname><given-names>M</given-names></name><name><surname>Majdzadeh</surname><given-names>R</given-names></name><name><surname>Majeed</surname><given-names>A</given-names></name><name><surname>Malekzadeh</surname><given-names>R</given-names></name><name><surname>Malta</surname><given-names>DC</given-names></name><name><surname>Mamun</surname><given-names>AA</given-names></name><name><surname>Manda</surname><given-names>A-L</given-names></name><name><surname>Manguerra</surname><given-names>H</given-names></name><name><surname>Manhertz</surname><given-names>T</given-names></name><name><surname>Mansournia</surname><given-names>MA</given-names></name><name><surname>Mantovani</surname><given-names>LG</given-names></name><name><surname>Mapoma</surname><given-names>CC</given-names></name><name><surname>Maravilla</surname><given-names>JC</given-names></name><name><surname>Marcenes</surname><given-names>W</given-names></name><name><surname>Marks</surname><given-names>A</given-names></name><name><surname>Martins-Melo</surname><given-names>FR</given-names></name><name><surname>Martopullo</surname><given-names>I</given-names></name><name><surname>MÃ¤rz</surname><given-names>W</given-names></name><name><surname>Marzan</surname><given-names>MB</given-names></name><name><surname>Mashamba-Thompson</surname><given-names>TP</given-names></name><name><surname>Massenburg</surname><given-names>BB</given-names></name><name><surname>Mathur</surname><given-names>MR</given-names></name><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>Maulik</surname><given-names>PK</given-names></name><name><surname>Mazidi</surname><given-names>M</given-names></name><name><surname>McAlinden</surname><given-names>C</given-names></name><name><surname>McGrath</surname><given-names>JJ</given-names></name><name><surname>McKee</surname><given-names>M</given-names></name><name><surname>Mehndiratta</surname><given-names>MM</given-names></name><name><surname>Mehrotra</surname><given-names>R</given-names></name><name><surname>Mehta</surname><given-names>KM</given-names></name><name><surname>Mehta</surname><given-names>V</given-names></name><name><surname>Mejia-Rodriguez</surname><given-names>F</given-names></name><name><surname>Mekonen</surname><given-names>T</given-names></name><name><surname>Melese</surname><given-names>A</given-names></name><name><surname>Melku</surname><given-names>M</given-names></name><name><surname>Meltzer</surname><given-names>M</given-names></name><name><surname>Memiah</surname><given-names>PTN</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name><name><surname>Mendoza</surname><given-names>W</given-names></name><name><surname>Mengistu</surname><given-names>DT</given-names></name><name><surname>Mengistu</surname><given-names>G</given-names></name><name><surname>Mensah</surname><given-names>GA</given-names></name><name><surname>Mereta</surname><given-names>ST</given-names></name><name><surname>Meretoja</surname><given-names>A</given-names></name><name><surname>Meretoja</surname><given-names>TJ</given-names></name><name><surname>Mestrovic</surname><given-names>T</given-names></name><name><surname>Mezerji</surname><given-names>NMG</given-names></name><name><surname>Miazgowski</surname><given-names>B</given-names></name><name><surname>Miazgowski</surname><given-names>T</given-names></name><name><surname>Millear</surname><given-names>AI</given-names></name><name><surname>Miller</surname><given-names>TR</given-names></name><name><surname>Miltz</surname><given-names>B</given-names></name><name><surname>Mini</surname><given-names>GK</given-names></name><name><surname>Mirarefin</surname><given-names>M</given-names></name><name><surname>Mirrakhimov</surname><given-names>EM</given-names></name><name><surname>Misganaw</surname><given-names>AT</given-names></name><name><surname>Mitchell</surname><given-names>PB</given-names></name><name><surname>Mitiku</surname><given-names>H</given-names></name><name><surname>Moazen</surname><given-names>B</given-names></name><name><surname>Mohajer</surname><given-names>B</given-names></name><name><surname>Mohammad</surname><given-names>KA</given-names></name><name><surname>Mohammadifard</surname><given-names>N</given-names></name><name><surname>Mohammadnia-Afrouzi</surname><given-names>M</given-names></name><name><surname>Mohammed</surname><given-names>MA</given-names></name><name><surname>Mohammed</surname><given-names>S</given-names></name><name><surname>Mohebi</surname><given-names>F</given-names></name><name><surname>Moitra</surname><given-names>M</given-names></name><name><surname>Mokdad</surname><given-names>AH</given-names></name><name><surname>Molokhia</surname><given-names>M</given-names></name><name><surname>Monasta</surname><given-names>L</given-names></name><name><surname>Moodley</surname><given-names>Y</given-names></name><name><surname>Moosazadeh</surname><given-names>M</given-names></name><name><surname>Moradi</surname><given-names>G</given-names></name><name><surname>Moradi-Lakeh</surname><given-names>M</given-names></name><name><surname>Moradinazar</surname><given-names>M</given-names></name><name><surname>Moraga</surname><given-names>P</given-names></name><name><surname>Morawska</surname><given-names>L</given-names></name><name><surname>Moreno VelÃ¡squez</surname><given-names>I</given-names></name><name><surname>Morgado-Da-Costa</surname><given-names>J</given-names></name><name><surname>Morrison</surname><given-names>SD</given-names></name><name><surname>Moschos</surname><given-names>MM</given-names></name><name><surname>Mountjoy-Venning</surname><given-names>WC</given-names></name><name><surname>Mousavi</surname><given-names>SM</given-names></name><name><surname>Mruts</surname><given-names>KB</given-names></name><name><surname>Muche</surname><given-names>AA</given-names></name><name><surname>Muchie</surname><given-names>KF</given-names></name><name><surname>Mueller</surname><given-names>UO</given-names></name><name><surname>Muhammed</surname><given-names>OS</given-names></name><name><surname>Mukhopadhyay</surname><given-names>S</given-names></name><name><surname>Muller</surname><given-names>K</given-names></name><name><surname>Mumford</surname><given-names>JE</given-names></name><name><surname>Murhekar</surname><given-names>M</given-names></name><name><surname>Musa</surname><given-names>J</given-names></name><name><surname>Musa</surname><given-names>KI</given-names></name><name><surname>Mustafa</surname><given-names>G</given-names></name><name><surname>Nabhan</surname><given-names>AF</given-names></name><name><surname>Nagata</surname><given-names>C</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Naheed</surname><given-names>A</given-names></name><name><surname>Nahvijou</surname><given-names>A</given-names></name><name><surname>Naik</surname><given-names>G</given-names></name><name><surname>Naik</surname><given-names>N</given-names></name><name><surname>Najafi</surname><given-names>F</given-names></name><name><surname>Naldi</surname><given-names>L</given-names></name><name><surname>Nam</surname><given-names>HS</given-names></name><name><surname>Nangia</surname><given-names>V</given-names></name><name><surname>Nansseu</surname><given-names>JR</given-names></name><name><surname>Nascimento</surname><given-names>BR</given-names></name><name><surname>Natarajan</surname><given-names>G</given-names></name><name><surname>Neamati</surname><given-names>N</given-names></name><name><surname>Negoi</surname><given-names>I</given-names></name><name><surname>Negoi</surname><given-names>RI</given-names></name><name><surname>Neupane</surname><given-names>S</given-names></name><name><surname>Newton</surname><given-names>CRJ</given-names></name><name><surname>Ngunjiri</surname><given-names>JW</given-names></name><name><surname>Nguyen</surname><given-names>AQ</given-names></name><name><surname>Nguyen</surname><given-names>HT</given-names></name><name><surname>Nguyen</surname><given-names>HLT</given-names></name><name><surname>Nguyen</surname><given-names>HT</given-names></name><name><surname>Nguyen</surname><given-names>LH</given-names></name><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Nguyen</surname><given-names>NB</given-names></name><name><surname>Nguyen</surname><given-names>SH</given-names></name><name><surname>Nichols</surname><given-names>E</given-names></name><name><surname>Ningrum</surname><given-names>DNA</given-names></name><name><surname>Nixon</surname><given-names>MR</given-names></name><name><surname>Nolutshungu</surname><given-names>N</given-names></name><name><surname>Nomura</surname><given-names>S</given-names></name><name><surname>Norheim</surname><given-names>OF</given-names></name><name><surname>Noroozi</surname><given-names>M</given-names></name><name><surname>Norrving</surname><given-names>B</given-names></name><name><surname>Noubiap</surname><given-names>JJ</given-names></name><name><surname>Nouri</surname><given-names>HR</given-names></name><name><surname>Nourollahpour Shiadeh</surname><given-names>M</given-names></name><name><surname>Nowroozi</surname><given-names>MR</given-names></name><name><surname>Nsoesie</surname><given-names>EO</given-names></name><name><surname>Nyasulu</surname><given-names>PS</given-names></name><name><surname>Odell</surname><given-names>CM</given-names></name><name><surname>Ofori-Asenso</surname><given-names>R</given-names></name><name><surname>Ogbo</surname><given-names>FA</given-names></name><name><surname>Oh</surname><given-names>I-H</given-names></name><name><surname>Oladimeji</surname><given-names>O</given-names></name><name><surname>Olagunju</surname><given-names>AT</given-names></name><name><surname>Olagunju</surname><given-names>TO</given-names></name><name><surname>Olivares</surname><given-names>PR</given-names></name><name><surname>Olsen</surname><given-names>HE</given-names></name><name><surname>Olusanya</surname><given-names>BO</given-names></name><name><surname>Ong</surname><given-names>KL</given-names></name><name><surname>Ong</surname><given-names>SK</given-names></name><name><surname>Oren</surname><given-names>E</given-names></name><name><surname>Ortiz</surname><given-names>A</given-names></name><name><surname>Ota</surname><given-names>E</given-names></name><name><surname>Otstavnov</surname><given-names>SS</given-names></name><name><surname>Ãverland</surname><given-names>S</given-names></name><name><surname>Owolabi</surname><given-names>MO</given-names></name><name><surname>P A</surname><given-names>M</given-names></name><name><surname>Pacella</surname><given-names>R</given-names></name><name><surname>Pakpour</surname><given-names>AH</given-names></name><name><surname>Pana</surname><given-names>A</given-names></name><name><surname>Panda-Jonas</surname><given-names>S</given-names></name><name><surname>Parisi</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>E-K</given-names></name><name><surname>Parry</surname><given-names>CDH</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Pati</surname><given-names>S</given-names></name><name><surname>Patil</surname><given-names>ST</given-names></name><name><surname>Patle</surname><given-names>A</given-names></name><name><surname>Patton</surname><given-names>GC</given-names></name><name><surname>Paturi</surname><given-names>VR</given-names></name><name><surname>Paulson</surname><given-names>KR</given-names></name><name><surname>Pearce</surname><given-names>N</given-names></name><name><surname>Pereira</surname><given-names>DM</given-names></name><name><surname>Perico</surname><given-names>N</given-names></name><name><surname>Pesudovs</surname><given-names>K</given-names></name><name><surname>Pham</surname><given-names>HQ</given-names></name><name><surname>Phillips</surname><given-names>MR</given-names></name><name><surname>Pigott</surname><given-names>DM</given-names></name><name><surname>Pillay</surname><given-names>JD</given-names></name><name><surname>Piradov</surname><given-names>MA</given-names></name><name><surname>Pirsaheb</surname><given-names>M</given-names></name><name><surname>Pishgar</surname><given-names>F</given-names></name><name><surname>Plana-Ripoll</surname><given-names>O</given-names></name><name><surname>Plass</surname><given-names>D</given-names></name><name><surname>Polinder</surname><given-names>S</given-names></name><name><surname>Popova</surname><given-names>S</given-names></name><name><surname>Postma</surname><given-names>MJ</given-names></name><name><surname>Pourshams</surname><given-names>A</given-names></name><name><surname>Poustchi</surname><given-names>H</given-names></name><name><surname>Prabhakaran</surname><given-names>D</given-names></name><name><surname>Prakash</surname><given-names>S</given-names></name><name><surname>Prakash</surname><given-names>V</given-names></name><name><surname>Purcell</surname><given-names>CA</given-names></name><name><surname>Purwar</surname><given-names>MB</given-names></name><name><surname>Qorbani</surname><given-names>M</given-names></name><name><surname>Quistberg</surname><given-names>DA</given-names></name><name><surname>Radfar</surname><given-names>A</given-names></name><name><surname>Rafay</surname><given-names>A</given-names></name><name><surname>Rafiei</surname><given-names>A</given-names></name><name><surname>Rahim</surname><given-names>F</given-names></name><name><surname>Rahimi</surname><given-names>K</given-names></name><name><surname>Rahimi-Movaghar</surname><given-names>A</given-names></name><name><surname>Rahimi-Movaghar</surname><given-names>V</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Rahman</surname><given-names>MH</given-names></name><name><surname>Rahman</surname><given-names>MA</given-names></name><name><surname>Rahman</surname><given-names>SU</given-names></name><name><surname>Rai</surname><given-names>RK</given-names></name><name><surname>Rajati</surname><given-names>F</given-names></name><name><surname>Ram</surname><given-names>U</given-names></name><name><surname>Ranjan</surname><given-names>P</given-names></name><name><surname>Ranta</surname><given-names>A</given-names></name><name><surname>Rao</surname><given-names>PC</given-names></name><name><surname>Rawaf</surname><given-names>DL</given-names></name><name><surname>Rawaf</surname><given-names>S</given-names></name><name><surname>Reddy</surname><given-names>KS</given-names></name><name><surname>Reiner</surname><given-names>RC</given-names></name><name><surname>Reinig</surname><given-names>N</given-names></name><name><surname>Reitsma</surname><given-names>MB</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name><name><surname>Renzaho</surname><given-names>AMN</given-names></name><name><surname>Resnikoff</surname><given-names>S</given-names></name><name><surname>Rezaei</surname><given-names>S</given-names></name><name><surname>Rezai</surname><given-names>MS</given-names></name><name><surname>Ribeiro</surname><given-names>ALP</given-names></name><name><surname>Roberts</surname><given-names>NLS</given-names></name><name><surname>Robinson</surname><given-names>SR</given-names></name><name><surname>Roever</surname><given-names>L</given-names></name><name><surname>Ronfani</surname><given-names>L</given-names></name><name><surname>Roshandel</surname><given-names>G</given-names></name><name><surname>Rostami</surname><given-names>A</given-names></name><name><surname>Roth</surname><given-names>GA</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Rubagotti</surname><given-names>E</given-names></name><name><surname>Sachdev</surname><given-names>PS</given-names></name><name><surname>Sadat</surname><given-names>N</given-names></name><name><surname>Saddik</surname><given-names>B</given-names></name><name><surname>Sadeghi</surname><given-names>E</given-names></name><name><surname>Saeedi Moghaddam</surname><given-names>S</given-names></name><name><surname>Safari</surname><given-names>H</given-names></name><name><surname>Safari</surname><given-names>Y</given-names></name><name><surname>Safari-Faramani</surname><given-names>R</given-names></name><name><surname>Safdarian</surname><given-names>M</given-names></name><name><surname>Safi</surname><given-names>S</given-names></name><name><surname>Safiri</surname><given-names>S</given-names></name><name><surname>Sagar</surname><given-names>R</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name><name><surname>Sahraian</surname><given-names>MA</given-names></name><name><surname>Sajadi</surname><given-names>HS</given-names></name><name><surname>Salam</surname><given-names>N</given-names></name><name><surname>Salama</surname><given-names>JS</given-names></name><name><surname>Salamati</surname><given-names>P</given-names></name><name><surname>Saleem</surname><given-names>K</given-names></name><name><surname>Saleem</surname><given-names>Z</given-names></name><name><surname>Salimi</surname><given-names>Y</given-names></name><name><surname>Salomon</surname><given-names>JA</given-names></name><name><surname>Salvi</surname><given-names>SS</given-names></name><name><surname>Salz</surname><given-names>I</given-names></name><name><surname>Samy</surname><given-names>AM</given-names></name><name><surname>Sanabria</surname><given-names>J</given-names></name><name><surname>Sang</surname><given-names>Y</given-names></name><name><surname>Santomauro</surname><given-names>DF</given-names></name><name><surname>Santos</surname><given-names>IS</given-names></name><name><surname>Santos</surname><given-names>JV</given-names></name><name><surname>Santric Milicevic</surname><given-names>MM</given-names></name><name><surname>Sao Jose</surname><given-names>BP</given-names></name><name><surname>Sardana</surname><given-names>M</given-names></name><name><surname>Sarker</surname><given-names>AR</given-names></name><name><surname>Sarrafzadegan</surname><given-names>N</given-names></name><name><surname>Sartorius</surname><given-names>B</given-names></name><name><surname>Sarvi</surname><given-names>S</given-names></name><name><surname>Sathian</surname><given-names>B</given-names></name><name><surname>Satpathy</surname><given-names>M</given-names></name><name><surname>Sawant</surname><given-names>AR</given-names></name><name><surname>Sawhney</surname><given-names>M</given-names></name><name><surname>Saxena</surname><given-names>S</given-names></name><name><surname>Saylan</surname><given-names>M</given-names></name><name><surname>Schaeffner</surname><given-names>E</given-names></name><name><surname>Schmidt</surname><given-names>MI</given-names></name><name><surname>Schneider</surname><given-names>IJC</given-names></name><name><surname>SchÃ¶ttker</surname><given-names>B</given-names></name><name><surname>Schwebel</surname><given-names>DC</given-names></name><name><surname>Schwendicke</surname><given-names>F</given-names></name><name><surname>Scott</surname><given-names>JG</given-names></name><name><surname>Sekerija</surname><given-names>M</given-names></name><name><surname>Sepanlou</surname><given-names>SG</given-names></name><name><surname>ServÃ¡n-Mori</surname><given-names>E</given-names></name><name><surname>Seyedmousavi</surname><given-names>S</given-names></name><name><surname>Shabaninejad</surname><given-names>H</given-names></name><name><surname>Shafieesabet</surname><given-names>A</given-names></name><name><surname>Shahbazi</surname><given-names>M</given-names></name><name><surname>Shaheen</surname><given-names>AA</given-names></name><name><surname>Shaikh</surname><given-names>MA</given-names></name><name><surname>Shams-Beyranvand</surname><given-names>M</given-names></name><name><surname>Shamsi</surname><given-names>M</given-names></name><name><surname>Shamsizadeh</surname><given-names>M</given-names></name><name><surname>Sharafi</surname><given-names>H</given-names></name><name><surname>Sharafi</surname><given-names>K</given-names></name><name><surname>Sharif</surname><given-names>M</given-names></name><name><surname>Sharif-Alhoseini</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>She</surname><given-names>J</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name><name><surname>Shi</surname><given-names>P</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Shigematsu</surname><given-names>M</given-names></name><name><surname>Shiri</surname><given-names>R</given-names></name><name><surname>Shirkoohi</surname><given-names>R</given-names></name><name><surname>Shishani</surname><given-names>K</given-names></name><name><surname>Shiue</surname><given-names>I</given-names></name><name><surname>Shokraneh</surname><given-names>F</given-names></name><name><surname>Shoman</surname><given-names>H</given-names></name><name><surname>Shrime</surname><given-names>MG</given-names></name><name><surname>Si</surname><given-names>S</given-names></name><name><surname>Siabani</surname><given-names>S</given-names></name><name><surname>Siddiqi</surname><given-names>TJ</given-names></name><name><surname>Sigfusdottir</surname><given-names>ID</given-names></name><name><surname>Sigurvinsdottir</surname><given-names>R</given-names></name><name><surname>Silva</surname><given-names>JP</given-names></name><name><surname>Silveira</surname><given-names>DGA</given-names></name><name><surname>Singam</surname><given-names>NSV</given-names></name><name><surname>Singh</surname><given-names>JA</given-names></name><name><surname>Singh</surname><given-names>NP</given-names></name><name><surname>Singh</surname><given-names>V</given-names></name><name><surname>Sinha</surname><given-names>DN</given-names></name><name><surname>Skiadaresi</surname><given-names>E</given-names></name><name><surname>Slepak</surname><given-names>ELN</given-names></name><name><surname>Sliwa</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Soares Filho</surname><given-names>AM</given-names></name><name><surname>Sobaih</surname><given-names>BH</given-names></name><name><surname>Sobhani</surname><given-names>S</given-names></name><name><surname>Sobngwi</surname><given-names>E</given-names></name><name><surname>Soneji</surname><given-names>SS</given-names></name><name><surname>Soofi</surname><given-names>M</given-names></name><name><surname>Soosaraei</surname><given-names>M</given-names></name><name><surname>Sorensen</surname><given-names>RJD</given-names></name><name><surname>Soriano</surname><given-names>JB</given-names></name><name><surname>Soyiri</surname><given-names>IN</given-names></name><name><surname>Sposato</surname><given-names>LA</given-names></name><name><surname>Sreeramareddy</surname><given-names>CT</given-names></name><name><surname>Srinivasan</surname><given-names>V</given-names></name><name><surname>Stanaway</surname><given-names>JD</given-names></name><name><surname>Stein</surname><given-names>DJ</given-names></name><name><surname>Steiner</surname><given-names>C</given-names></name><name><surname>Steiner</surname><given-names>TJ</given-names></name><name><surname>Stokes</surname><given-names>MA</given-names></name><name><surname>Stovner</surname><given-names>LJ</given-names></name><name><surname>Subart</surname><given-names>ML</given-names></name><name><surname>Sudaryanto</surname><given-names>A</given-names></name><name><surname>Sufiyan</surname><given-names>MB</given-names></name><name><surname>Sunguya</surname><given-names>BF</given-names></name><name><surname>Sur</surname><given-names>PJ</given-names></name><name><surname>Sutradhar</surname><given-names>I</given-names></name><name><surname>Sykes</surname><given-names>BL</given-names></name><name><surname>Sylte</surname><given-names>DO</given-names></name><name><surname>TabarÃ©s-Seisdedos</surname><given-names>R</given-names></name><name><surname>Tadakamadla</surname><given-names>SK</given-names></name><name><surname>Tadesse</surname><given-names>BT</given-names></name><name><surname>Tandon</surname><given-names>N</given-names></name><name><surname>Tassew</surname><given-names>SG</given-names></name><name><surname>Tavakkoli</surname><given-names>M</given-names></name><name><surname>Taveira</surname><given-names>N</given-names></name><name><surname>Taylor</surname><given-names>HR</given-names></name><name><surname>Tehrani-Banihashemi</surname><given-names>A</given-names></name><name><surname>Tekalign</surname><given-names>TG</given-names></name><name><surname>Tekelemedhin</surname><given-names>SW</given-names></name><name><surname>Tekle</surname><given-names>MG</given-names></name><name><surname>Temesgen</surname><given-names>H</given-names></name><name><surname>Temsah</surname><given-names>M-H</given-names></name><name><surname>Temsah</surname><given-names>O</given-names></name><name><surname>Terkawi</surname><given-names>AS</given-names></name><name><surname>Teweldemedhin</surname><given-names>M</given-names></name><name><surname>Thankappan</surname><given-names>KR</given-names></name><name><surname>Thomas</surname><given-names>N</given-names></name><name><surname>Tilahun</surname><given-names>B</given-names></name><name><surname>To</surname><given-names>QG</given-names></name><name><surname>Tonelli</surname><given-names>M</given-names></name><name><surname>Topor-Madry</surname><given-names>R</given-names></name><name><surname>Topouzis</surname><given-names>F</given-names></name><name><surname>Torre</surname><given-names>AE</given-names></name><name><surname>Tortajada-GirbÃ©s</surname><given-names>M</given-names></name><name><surname>Touvier</surname><given-names>M</given-names></name><name><surname>Tovani-Palone</surname><given-names>MR</given-names></name><name><surname>Towbin</surname><given-names>JA</given-names></name><name><surname>Tran</surname><given-names>BX</given-names></name><name><surname>Tran</surname><given-names>KB</given-names></name><name><surname>Troeger</surname><given-names>CE</given-names></name><name><surname>Truelsen</surname><given-names>TC</given-names></name><name><surname>Tsilimbaris</surname><given-names>MK</given-names></name><name><surname>Tsoi</surname><given-names>D</given-names></name><name><surname>Tudor Car</surname><given-names>L</given-names></name><name><surname>Tuzcu</surname><given-names>EM</given-names></name><name><surname>Ukwaja</surname><given-names>KN</given-names></name><name><surname>Ullah</surname><given-names>I</given-names></name><name><surname>Undurraga</surname><given-names>EA</given-names></name><name><surname>Unutzer</surname><given-names>J</given-names></name><name><surname>Updike</surname><given-names>RL</given-names></name><name><surname>Usman</surname><given-names>MS</given-names></name><name><surname>Uthman</surname><given-names>OA</given-names></name><name><surname>Vaduganathan</surname><given-names>M</given-names></name><name><surname>Vaezi</surname><given-names>A</given-names></name><name><surname>Valdez</surname><given-names>PR</given-names></name><name><surname>Varughese</surname><given-names>S</given-names></name><name><surname>Vasankari</surname><given-names>TJ</given-names></name><name><surname>Venketasubramanian</surname><given-names>N</given-names></name><name><surname>Villafaina</surname><given-names>S</given-names></name><name><surname>Violante</surname><given-names>FS</given-names></name><name><surname>Vladimirov</surname><given-names>SK</given-names></name><name><surname>Vlassov</surname><given-names>V</given-names></name><name><surname>Vollset</surname><given-names>SE</given-names></name><name><surname>Vosoughi</surname><given-names>K</given-names></name><name><surname>Vujcic</surname><given-names>IS</given-names></name><name><surname>Wagnew</surname><given-names>FS</given-names></name><name><surname>Waheed</surname><given-names>Y</given-names></name><name><surname>Waller</surname><given-names>SG</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y-P</given-names></name><name><surname>Weiderpass</surname><given-names>E</given-names></name><name><surname>Weintraub</surname><given-names>RG</given-names></name><name><surname>Weiss</surname><given-names>DJ</given-names></name><name><surname>Weldegebreal</surname><given-names>F</given-names></name><name><surname>Weldegwergs</surname><given-names>KG</given-names></name><name><surname>Werdecker</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>TE</given-names></name><name><surname>Whiteford</surname><given-names>HA</given-names></name><name><surname>Widecka</surname><given-names>J</given-names></name><name><surname>Wijeratne</surname><given-names>T</given-names></name><name><surname>Wilner</surname><given-names>LB</given-names></name><name><surname>Wilson</surname><given-names>S</given-names></name><name><surname>Winkler</surname><given-names>AS</given-names></name><name><surname>Wiyeh</surname><given-names>AB</given-names></name><name><surname>Wiysonge</surname><given-names>CS</given-names></name><name><surname>Wolfe</surname><given-names>CDA</given-names></name><name><surname>Woolf</surname><given-names>AD</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y-C</given-names></name><name><surname>Wyper</surname><given-names>GMA</given-names></name><name><surname>Xavier</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Yadgir</surname><given-names>S</given-names></name><name><surname>Yadollahpour</surname><given-names>A</given-names></name><name><surname>Yahyazadeh Jabbari</surname><given-names>SH</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Yan</surname><given-names>LL</given-names></name><name><surname>Yano</surname><given-names>Y</given-names></name><name><surname>Yaseri</surname><given-names>M</given-names></name><name><surname>Yasin</surname><given-names>YJ</given-names></name><name><surname>Yeshaneh</surname><given-names>A</given-names></name><name><surname>Yimer</surname><given-names>EM</given-names></name><name><surname>Yip</surname><given-names>P</given-names></name><name><surname>Yisma</surname><given-names>E</given-names></name><name><surname>Yonemoto</surname><given-names>N</given-names></name><name><surname>Yoon</surname><given-names>S-J</given-names></name><name><surname>Yotebieng</surname><given-names>M</given-names></name><name><surname>Younis</surname><given-names>MZ</given-names></name><name><surname>Yousefifard</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Zadnik</surname><given-names>V</given-names></name><name><surname>Zaidi</surname><given-names>Z</given-names></name><name><surname>Zaman</surname><given-names>SB</given-names></name><name><surname>Zamani</surname><given-names>M</given-names></name><name><surname>Zare</surname><given-names>Z</given-names></name><name><surname>Zeleke</surname><given-names>AJ</given-names></name><name><surname>Zenebe</surname><given-names>ZM</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Zodpey</surname><given-names>S</given-names></name><name><surname>Zucker</surname><given-names>I</given-names></name><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Murray</surname><given-names>CJL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title><source>The Lancet</source><volume>392</volume><fpage>1789</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32279-7</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeon</surname><given-names>OH</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Laberge</surname><given-names>R-M</given-names></name><name><surname>Demaria</surname><given-names>M</given-names></name><name><surname>Rathod</surname><given-names>S</given-names></name><name><surname>Vasserot</surname><given-names>AP</given-names></name><name><surname>Chung</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Poon</surname><given-names>Y</given-names></name><name><surname>David</surname><given-names>N</given-names></name><name><surname>Baker</surname><given-names>DJ</given-names></name><name><surname>van Deursen</surname><given-names>JM</given-names></name><name><surname>Campisi</surname><given-names>J</given-names></name><name><surname>Elisseeff</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment</article-title><source>Nature Medicine</source><volume>23</volume><fpage>775</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1038/nm.4324</pub-id><pub-id pub-id-type="pmid">28436958</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallewaard</surname><given-names>JW</given-names></name><name><surname>Terheggen</surname><given-names>MAMB</given-names></name><name><surname>Groen</surname><given-names>GJ</given-names></name><name><surname>Sluijter</surname><given-names>ME</given-names></name><name><surname>Derby</surname><given-names>R</given-names></name><name><surname>Kapural</surname><given-names>L</given-names></name><name><surname>Mekhail</surname><given-names>N</given-names></name><name><surname>van Kleef</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>15. Discogenic low back pain</article-title><source>Pain Practice</source><volume>10</volume><fpage>560</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1111/j.1533-2500.2010.00408.x</pub-id><pub-id pub-id-type="pmid">20825564</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamei</surname><given-names>H</given-names></name><name><surname>Ishii</surname><given-names>T</given-names></name><name><surname>Nishii</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Semaphorin 3A regulates alveolar bone remodeling on orthodontic tooth movement</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>9243</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-13217-x</pub-id><pub-id pub-id-type="pmid">35654941</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnamurthy</surname><given-names>J</given-names></name><name><surname>Ramsey</surname><given-names>MR</given-names></name><name><surname>Ligon</surname><given-names>KL</given-names></name><name><surname>Torrice</surname><given-names>C</given-names></name><name><surname>Koh</surname><given-names>A</given-names></name><name><surname>Bonner-Weir</surname><given-names>S</given-names></name><name><surname>Sharpless</surname><given-names>NE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>p16INK4a induces an age-dependent decline in islet regenerative potential</article-title><source>Nature</source><volume>443</volume><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/nature05092</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>HB</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Jin</surname><given-names>HM</given-names></name><name><surname>Ha</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Takeshita</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>H-M</given-names></name><name><surname>Kim</surname><given-names>H-H</given-names></name><name><surname>Lee</surname><given-names>ZH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration</article-title><source>Blood</source><volume>105</volume><fpage>2963</fpage><lpage>2969</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-07-2534</pub-id><pub-id pub-id-type="pmid">15585657</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Chung</surname><given-names>CK</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The efficacy of conventional radiofrequency denervation in patients with chronic low back pain originating from the facet joints: a meta-analysis of randomized controlled trials</article-title><source>The Spine Journal</source><volume>17</volume><fpage>1770</fpage><lpage>1780</lpage><pub-id pub-id-type="doi">10.1016/j.spinee.2017.05.006</pub-id><pub-id pub-id-type="pmid">28576500</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Zhan</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Hua</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Exosomes from mesenchymal stem cells modulate endoplasmic reticulum stress to protect against nucleus pulposus cell death and ameliorate intervertebral disc degeneration in vivo</article-title><source>Theranostics</source><volume>9</volume><fpage>4084</fpage><lpage>4100</lpage><pub-id pub-id-type="doi">10.7150/thno.33638</pub-id><pub-id pub-id-type="pmid">31281533</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>An</surname><given-names>SB</given-names></name><name><surname>Jung</surname><given-names>M</given-names></name><name><surname>Joshi</surname><given-names>HP</given-names></name><name><surname>Kumar</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>J-R</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>B-S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Local delivery of senolytic drug inhibits intervertebral disc degeneration and restores intervertebral disc structure</article-title><source>Advanced Healthcare Materials</source><volume>11</volume><elocation-id>e2101483</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.202101483</pub-id><pub-id pub-id-type="pmid">34699690</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LÃ³pez-OtÃ­n</surname><given-names>C</given-names></name><name><surname>Blasco</surname><given-names>MA</given-names></name><name><surname>Partridge</surname><given-names>L</given-names></name><name><surname>Serrano</surname><given-names>M</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The hallmarks of aging</article-title><source>Cell</source><volume>153</volume><fpage>1194</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.05.039</pub-id><pub-id pub-id-type="pmid">23746838</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maas</surname><given-names>ET</given-names></name><name><surname>Ostelo</surname><given-names>RWJG</given-names></name><name><surname>Niemisto</surname><given-names>L</given-names></name><name><surname>Jousimaa</surname><given-names>J</given-names></name><name><surname>Hurri</surname><given-names>H</given-names></name><name><surname>Malmivaara</surname><given-names>A</given-names></name><name><surname>van Tulder</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Radiofrequency denervation for chronic low back pain</article-title><source>The Cochrane Database of Systematic Reviews</source><volume>2015</volume><elocation-id>CD008572</elocation-id><pub-id pub-id-type="doi">10.1002/14651858.CD008572.pub2</pub-id><pub-id pub-id-type="pmid">26495910</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>C</given-names></name><name><surname>Underwood</surname><given-names>M</given-names></name><name><surname>Buchbinder</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Non-specific low back pain</article-title><source>Lancet</source><volume>389</volume><fpage>736</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30970-9</pub-id><pub-id pub-id-type="pmid">27745712</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>TJ</given-names></name><name><surname>Ingleton</surname><given-names>PM</given-names></name><name><surname>Underwood</surname><given-names>JC</given-names></name><name><surname>Michelangeli</surname><given-names>VP</given-names></name><name><surname>Hunt</surname><given-names>NH</given-names></name><name><surname>Melick</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Parathyroid hormone-responsive adenylate cyclase in induced transplantable osteogenic rat sarcoma</article-title><source>Nature</source><volume>260</volume><fpage>436</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1038/260436a0</pub-id><pub-id pub-id-type="pmid">1062678</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>K</given-names></name><name><surname>Aota</surname><given-names>Y</given-names></name><name><surname>Muehleman</surname><given-names>C</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Okuma</surname><given-names>M</given-names></name><name><surname>Thonar</surname><given-names>EJ</given-names></name><name><surname>Andersson</surname><given-names>GB</given-names></name><name><surname>An</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A novel rabbit model of mild, reproducible disc degeneration by an anulus needle puncture: Correlation between the degree of disc injury and radiological and histological appearances of disc degeneration</article-title><source>Spine</source><volume>30</volume><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1097/01.brs.0000148152.04401.20</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>S</given-names></name><name><surname>Yonenobu</surname><given-names>K</given-names></name><name><surname>Oono</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Experimental cervical spondylosis in the mouse</article-title><source>Spine</source><volume>16</volume><fpage>S495</fpage><lpage>S500</lpage><pub-id pub-id-type="doi">10.1097/00007632-199110001-00008</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizoguchi</surname><given-names>T</given-names></name><name><surname>Muto</surname><given-names>A</given-names></name><name><surname>Udagawa</surname><given-names>N</given-names></name><name><surname>Arai</surname><given-names>A</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Hosoya</surname><given-names>A</given-names></name><name><surname>Ninomiya</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Kinugawa</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Nakamichi</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Nagasawa</surname><given-names>S</given-names></name><name><surname>Oda</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Tagaya</surname><given-names>M</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Identification of cell cycle-arrested quiescent osteoclast precursors in vivo</article-title><source>The Journal of Cell Biology</source><volume>184</volume><fpage>541</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1083/jcb.200806139</pub-id><pub-id pub-id-type="pmid">19237598</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>SW</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lynch</surname><given-names>CD</given-names></name><name><surname>Sheetz</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Netrin-1 attracts axons through FAK-dependent mechanotransduction</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>11574</fpage><lpage>11585</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0999-12.2012</pub-id><pub-id pub-id-type="pmid">22915102</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muralidharan</surname><given-names>A</given-names></name><name><surname>Sotocinal</surname><given-names>SG</given-names></name><name><surname>Yousefpour</surname><given-names>N</given-names></name><name><surname>Akkurt</surname><given-names>N</given-names></name><name><surname>Lima</surname><given-names>LV</given-names></name><name><surname>Tansley</surname><given-names>S</given-names></name><name><surname>Parisien</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Austin</surname><given-names>J-S</given-names></name><name><surname>Ham</surname><given-names>B</given-names></name><name><surname>Dutra</surname><given-names>GM</given-names></name><name><surname>Rousseau</surname><given-names>P</given-names></name><name><surname>Maldonado-Bouchard</surname><given-names>S</given-names></name><name><surname>Clark</surname><given-names>T</given-names></name><name><surname>Rosen</surname><given-names>SF</given-names></name><name><surname>Majeed</surname><given-names>MR</given-names></name><name><surname>Silva</surname><given-names>O</given-names></name><name><surname>Nejade</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Donayre Pimentel</surname><given-names>S</given-names></name><name><surname>Nielsen</surname><given-names>CS</given-names></name><name><surname>Neely</surname><given-names>GG</given-names></name><name><surname>Autexier</surname><given-names>C</given-names></name><name><surname>Diatchenko</surname><given-names>L</given-names></name><name><surname>Ribeiro-da-Silva</surname><given-names>A</given-names></name><name><surname>Mogil</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Long-term male-specific chronic pain via telomere- and p53âmediated spinal cord cellular senescence</article-title><source>The Journal of Clinical Investigation</source><volume>132</volume><elocation-id>e151817</elocation-id><pub-id pub-id-type="doi">10.1172/JCI151817</pub-id><pub-id pub-id-type="pmid">35426375</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nevitt</surname><given-names>MC</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Dore</surname><given-names>RK</given-names></name><name><surname>Reginster</surname><given-names>J-Y</given-names></name><name><surname>Kiel</surname><given-names>DP</given-names></name><name><surname>Zanchetta</surname><given-names>JR</given-names></name><name><surname>Glass</surname><given-names>EV</given-names></name><name><surname>Krege</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Reduced risk of back pain following teriparatide treatment: a meta-analysis</article-title><source>Osteoporosis International</source><volume>17</volume><fpage>273</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1007/s00198-005-2013-2</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>S</given-names></name><name><surname>Ling</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Deng</surname><given-names>R</given-names></name><name><surname>Crane</surname><given-names>JL</given-names></name><name><surname>Skolasky</surname><given-names>R</given-names></name><name><surname>Demehri</surname><given-names>S</given-names></name><name><surname>Zhen</surname><given-names>G</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Lyu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sensory innervation in porous endplates by Netrin-1 from osteoclasts mediates PGE2-induced spinal hypersensitivity in mice</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>5643</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13476-9</pub-id><pub-id pub-id-type="pmid">31822662</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadakis</surname><given-names>M</given-names></name><name><surname>Sapkas</surname><given-names>G</given-names></name><name><surname>Papadopoulos</surname><given-names>EC</given-names></name><name><surname>Katonis</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Pathophysiology and biomechanics of the aging spine</article-title><source>The Open Orthopaedics Journal</source><volume>5</volume><fpage>335</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.2174/1874325001105010335</pub-id><pub-id pub-id-type="pmid">21966338</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qaseem</surname><given-names>A</given-names></name><name><surname>Wilt</surname><given-names>TJ</given-names></name><name><surname>McLean</surname><given-names>RM</given-names></name><name><surname>Forciea</surname><given-names>MA</given-names></name><collab>Clinical Guidelines Committee of the American College of Physicians</collab><name><surname>Denberg</surname><given-names>TD</given-names></name><name><surname>Barry</surname><given-names>MJ</given-names></name><name><surname>Boyd</surname><given-names>C</given-names></name><name><surname>Chow</surname><given-names>RD</given-names></name><name><surname>Fitterman</surname><given-names>N</given-names></name><name><surname>Harris</surname><given-names>RP</given-names></name><name><surname>Humphrey</surname><given-names>LL</given-names></name><name><surname>Vijan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the american college of physicians</article-title><source>Annals of Internal Medicine</source><volume>166</volume><fpage>514</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.7326/M16-2367</pub-id><pub-id pub-id-type="pmid">28192789</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>AG</given-names></name><name><surname>Rodriguez-Soto</surname><given-names>AE</given-names></name><name><surname>Burghardt</surname><given-names>AJ</given-names></name><name><surname>Berven</surname><given-names>S</given-names></name><name><surname>Majumdar</surname><given-names>S</given-names></name><name><surname>Lotz</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Morphology of the human vertebral endplate</article-title><source>Journal of Orthopaedic Research</source><volume>30</volume><fpage>280</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1002/jor.21513</pub-id><pub-id pub-id-type="pmid">21812023</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roelofs</surname><given-names>PDDM</given-names></name><name><surname>Deyo</surname><given-names>RA</given-names></name><name><surname>Koes</surname><given-names>BW</given-names></name><name><surname>Scholten</surname><given-names>RJPM</given-names></name><name><surname>van Tulder</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Non-steroidal anti-inflammatory drugs for low back pain</article-title><source>The Cochrane Database of Systematic Reviews</source><volume>2008</volume><elocation-id>CD000396</elocation-id><pub-id pub-id-type="doi">10.1002/14651858.CD000396.pub3</pub-id><pub-id pub-id-type="pmid">18253976</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serafini</surname><given-names>T</given-names></name><name><surname>Colamarino</surname><given-names>SA</given-names></name><name><surname>Leonardo</surname><given-names>ED</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Beddington</surname><given-names>R</given-names></name><name><surname>Skarnes</surname><given-names>WC</given-names></name><name><surname>Tessier-Lavigne</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system</article-title><source>Cell</source><volume>87</volume><fpage>1001</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81795-x</pub-id><pub-id pub-id-type="pmid">8978605</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheyn</surname><given-names>D</given-names></name><name><surname>Ben-David</surname><given-names>S</given-names></name><name><surname>Tawackoli</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Salehi</surname><given-names>K</given-names></name><name><surname>Bez</surname><given-names>M</given-names></name><name><surname>De Mel</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><name><surname>Roth</surname><given-names>J</given-names></name><name><surname>Avalos</surname><given-names>P</given-names></name><name><surname>Giaconi</surname><given-names>JC</given-names></name><name><surname>Yameen</surname><given-names>H</given-names></name><name><surname>Hazanov</surname><given-names>L</given-names></name><name><surname>Seliktar</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Gazit</surname><given-names>D</given-names></name><name><surname>Gazit</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human iPSCs can be differentiated into notochordal cells that reduce intervertebral disc degeneration in a porcine model</article-title><source>Theranostics</source><volume>9</volume><fpage>7506</fpage><lpage>7524</lpage><pub-id pub-id-type="doi">10.7150/thno.34898</pub-id><pub-id pub-id-type="pmid">31695783</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>T</given-names></name><name><surname>Valentino</surname><given-names>KM</given-names></name><name><surname>Seaman</surname><given-names>C</given-names></name><name><surname>Cooper</surname><given-names>HM</given-names></name><name><surname>Richards</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Expression of the netrin-1 receptor, deleted in colorectal cancer (DCC), is largely confined to projecting neurons in the developing forebrain</article-title><source>The Journal of Comparative Neurology</source><volume>416</volume><fpage>201</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1002/(sici)1096-9861(20000110)416:2&lt;201::aid-cne6&gt;3.0.co;2-z</pub-id><pub-id pub-id-type="pmid">10581466</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taher</surname><given-names>F</given-names></name><name><surname>Essig</surname><given-names>D</given-names></name><name><surname>Lebl</surname><given-names>DR</given-names></name><name><surname>Hughes</surname><given-names>AP</given-names></name><name><surname>Sama</surname><given-names>AA</given-names></name><name><surname>Cammisa</surname><given-names>FP</given-names></name><name><surname>Girardi</surname><given-names>FP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Lumbar degenerative disc disease: current and future concepts of diagnosis and management</article-title><source>Advances in Orthopedics</source><volume>2012</volume><elocation-id>970752</elocation-id><pub-id pub-id-type="doi">10.1155/2012/970752</pub-id><pub-id pub-id-type="pmid">22567411</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>RE</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Minichiello</surname><given-names>L</given-names></name><name><surname>Riddle</surname><given-names>RC</given-names></name><name><surname>Venkatesan</surname><given-names>A</given-names></name><name><surname>Clemens</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>NGF-TrkA signaling in sensory nerves is required for skeletal adaptation to mechanical loads in mice</article-title><source>PNAS</source><volume>114</volume><fpage>E3632</fpage><lpage>E3641</lpage><pub-id pub-id-type="doi">10.1073/pnas.1701054114</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Cai</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>XH</given-names></name><name><surname>Wu</surname><given-names>XT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Aging and age related stresses: a senescence mechanism of intervertebral disc degeneration</article-title><source>Osteoarthritis and Cartilage</source><volume>24</volume><fpage>398</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2015.09.019</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Xian</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Crane</surname><given-names>J</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Zhen</surname><given-names>G</given-names></name><name><surname>Bian</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>Qiu</surname><given-names>T</given-names></name><name><surname>Pickarski</surname><given-names>M</given-names></name><name><surname>Duong</surname><given-names>LT</given-names></name><name><surname>Windle</surname><given-names>JJ</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Liao</surname><given-names>E</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis</article-title><source>Nature Medicine</source><volume>20</volume><fpage>1270</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1038/nm.3668</pub-id><pub-id pub-id-type="pmid">25282358</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Lyu</surname><given-names>X</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Ford</surname><given-names>NC</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>PGE2/EP4 skeleton interoception activity reduces vertebral endplate porosity and spinal pain with low-dose celecoxib</article-title><source>Bone Research</source><volume>9</volume><elocation-id>36</elocation-id><pub-id pub-id-type="doi">10.1038/s41413-021-00155-z</pub-id><pub-id pub-id-type="pmid">34334792</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>G</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Ford</surname><given-names>NC</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mechanisms of bone pain: Progress in research from bench to bedside</article-title><source>Bone Research</source><volume>10</volume><elocation-id>44</elocation-id><pub-id pub-id-type="doi">10.1038/s41413-022-00217-w</pub-id><pub-id pub-id-type="pmid">35668080</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhen</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Skolasky</surname><given-names>RL</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Kuliwaba</surname><given-names>J</given-names></name><name><surname>Ni</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Findlay</surname><given-names>D</given-names></name><name><surname>Eltzschig</surname><given-names>HK</given-names></name><name><surname>Ouyang</surname><given-names>HW</given-names></name><name><surname>Crane</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>F-Q</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain</article-title><source>Journal of Clinical Investigation</source><volume>129</volume><fpage>1076</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1172/JCI121561</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92889.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ryu</surname><given-names>Vitaly</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Fundamental</kwd></kwd-group></front-stub><body><p>This <bold>fundamental</bold> study advances our understanding of the role of senescent osteoclasts (SnOCs) in the pathogenesis of spine instability. The authors provide <bold>compelling</bold> evidence for the SnOCs to induce sensory nerve innervation. Accordingly, reduction of SnOCs by the senolytic drug Navitoclax markedly reduces spinal pain sensitivity. This work will be of broad interest to regenerative biologists working on spinal pain.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92889.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In this study, Pan DY et al. discovered that the clearance of senescent osteoclasts can lead to a reduction in sensory nerve innervation. This reduction is achieved through the attenuation of Netrin-1 and NGF levels, as well as the regulation of H-type vessels, resulting in a decrease in pain-related behavior. The experiments are well-designed. The results are clearly presented, and the legends are also clear and informative. Their findings represent a potential treatment for spine pain utilizing senolytic drugs.</p><p>Strengths:</p><p>Rigorous data, well-designed experiments as well as significant innovation make this manuscript stand out.</p><p>Weaknesses:</p><p>All my concerns have been well addressed, no further comments.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92889.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This manuscript examined the underlying mechanisms between senescent osteoclasts (SnOCs) and lumbar spine instability (LSI) or aging. They first showed that greater numbers of SnOCs are observed in mouse models of LSI or aging, and these SnOCs are associated with induced sensory nerve innervation, as well as the growth of H-type vessels, in the porous endplate. Then, the deletion of senescent cells by administration of the senolytic drug Navitoclax (ABT263) results in significantly less spinal hypersensitivity, spinal degeneration, porosity of the endplate, sensory nerve innervation, and H-type vessel growth in the endplate. Finally, they also found that there is greater SnOC-mediated secretion of Netrin-1 and NGF, two well-established sensory nerve growth factors, compared to non-senescent OCs. The study is well conducted and data strongly support the idea.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92889.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This research article reports that a greater number of senescent osteoclasts (SnOCs), which produce Netrin-1 and NGF, are responsible for innervation in the LSI and aging animal models.</p><p>Strengths:</p><p>The research is based on previous findings in the authors' lab and the fact that the IVD structure was restored by treatment with ABT263. The logic is clear and clarifies the pathological role of SnOCs, suggesting the potential utilization of senolytic drugs for the treatment of LBP. Generally, the study is of good quality and the data is convincing.</p><p>Weaknesses:</p><p>All my concerns have been well addressed, no further comments.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.92889.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Dayu</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Benkato</surname><given-names>Kheiria Gamal</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Xuequan</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Jinjian</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Vijay</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wan</surname><given-names>Mei</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Junying</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins Medicine</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Xu</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authorsâ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>In this study, Pan DY et al. discovered that the clearance of senescent osteoclasts can lead to a reduction in sensory nerve innervation. This reduction is achieved through the attenuation of Netrin-1 and NGF levels, as well as the regulation of H-type vessels, resulting in a decrease in pain-related behavior. The experiments are well-designed. The results are clearly presented, and the legends are also clear and informative. Their findings represent a potential treatment for spine pain utilizing senolytic drugs.</p><p>Strengths:</p><p>Rigorous data, well-designed experiments as well as significant innovation make this manuscript stand out.</p><p>Weaknesses:</p><p>Quantification of histology and detailed statistical analysis will further strengthen this manuscript.</p><p>I have the following specific comments.</p><p>(1) Since defining senescent cells solely based on one or two markers (SA-Î²-gal and p16) may not provide a robust characterization, it would be advisable to employ another wellestablished senescence marker, such as Î³-H2AX or HMGB1, to corroborate the observed increase in senescent osteoclasts following LSI and aging.</p></disp-quote><p>We value the comments provided by the reviewer. In accordance with your suggestion, we have performed co-staining of HMGB1 with Trap in Supplementary Figure 1 to corroborate the observed augmentation of senescent osteoclasts following LSI and aging.</p><fig id="sa4fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-sa4-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(2) The connection between heightened Netrin-1 secretion by senescent osteoclasts following LSI or aging and its relevance to pain warrants thorough discussion within the manuscript to provide a comprehensive understanding of the entire narrative.</p></disp-quote><p>We appreciate the reviewer's insightful comments. We have thoroughly addressed the entire narrative in the revised manuscript, as outlined below:</p><p>During lumbar spine instability (LSI) or aging, endplates undergo ossification, leading to elevated osteoclast activity and increased porosity1-4. The progressive porous transformation of endplates, accompanied by a narrowed intervertebral disc (IVD) space, is a hallmark of spinal degeneration4,5. Considering that pain arises from nociceptors, it is plausible that low back pain (LBP) may be attributed to sensory innervation within endplates. Additionally, porous endplates exhibit higher nerve density compared to normal endplates or degenerative nucleus pulposus6. Netrin-1, a crucial axon guidance factor facilitating nerve protrusion, has been implicated in this process7-9. The receptor mediating Netrin-1-induced neuronal sprouting, deleted in colorectal cancer (DCC), was found to co-localize with CGRP+ sensory nerve fibers in endplates after LSI surgery10,11. In summary, during LSI or aging, osteoclastic lineage cells secrete Netrin-1, inducing extrusion and innervation of CGRP+ sensory nerve fibers within the spaces created by osteoclast resorption. This Netrin-1/DCC-mediated pain signal is subsequently transmitted to the dorsal root ganglion (DRG) or higher brain levels.</p><disp-quote content-type="editor-comment"><p>(3) It appears that the quantitative data for TRAP staining in Figure 1j is missing.</p></disp-quote><p>We appreciate the reviewer's comments. We have added the statistical data of TRAP staining (Figure. 1p) to Figure 1 in the revised manuscript.</p><fig id="sa4fig2" position="float"><label>Author response image 2.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-sa4-fig2-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(4) Regarding Figure 6, could you please specify which panels were analyzed using a t-test and which ones were subjected to ANOVA? Alternatively, were all the panels in Figure 6 analyzed using ANOVA?</p></disp-quote><p>We appreciate the reviewerâs comments here. Upon careful review, we have ensured that quantitative data in panels b, c, and f are analyzed using t-tests, while panels d, e, and g are subjected to one-way ANOVA. These updates have been reflected in the revised figure legend.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>This manuscript examined the underlying mechanisms between senescent osteoclasts (SnOCs) and lumbar spine instability (LSI) or aging. They first showed that greater numbers of SnOCs are observed in mouse models of LSI or aging, and these SnOCs are associated with induced sensory nerve innervation, as well as the growth of H-type vessels, in the porous endplate. Then, the deletion of senescent cells by administration of the senolytic drug Navitoclax (ABT263) results in significantly less spinal hypersensitivity, spinal degeneration, porosity of the endplate, sensory nerve innervation, and H-type vessel growth in the endplate. Finally, they also found that there is greater SnOCmediated secretion of Netrin-1 and NGF, two well-established sensory nerve growth factors, compared to non-senescent OCs. The study is well conducted and data strongly support the idea. However, some minor issues need to be addressed.</p><p>(1) In Figure 2C, &quot;Number of SnCs/mm2&quot;, SnCs should be SnOCs.</p></disp-quote><p>We apologize for the oversight. This has been rectified in the revised manuscript.</p><fig id="sa4fig3" position="float"><label>Author response image 3.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-sa4-fig3-v1.tif"/></fig><p>(2) In Figure 3A-E, is there any statistical difference between groups Young and Aged+PBS?</p><p>We appreciate the reviewer's comments. Following your recommendation, we conducted additional statistical analyses to compare the young and PBS-treated aged mice, and we have incorporated these findings into the revised manuscript. The data reveals a significant increased paw withdrawal frequency (PWF) in aged mice treated with PBS compared with young mice, particularly at 0.4g instead of 0.07g (Figure 3a, 3b). Moreover, aged mice treated with PBS exhibited a significant reduction in both distance traveled and active time when compared to young mice (Figure. 3d, 3e). Additionally, PBS-treated aged mice demonstrated a significantly shortened heat response time relative to young mice (Figure. 3c).</p><fig id="sa4fig4" position="float"><label>Author response image 4.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-sa4-fig4-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(3) Again, is there any statistical difference between the Young and Aged+PBS groups in Figure 4F-K?</p></disp-quote><p>We appreciate the reviewer's comments. As per your suggestion, we conducted a thorough analysis to determine the statistical differences between the young and aged+PBS groups, and these statistical results have been implemented in the revised manuscript. The caudal endplates of L4/5 in PBS-treated aged mice exhibited a significant increase in endplate porosity (Figure. 4f) and trabecular separation (Tb.Sp) (Figure. 4g) compared to young mice.</p><p>Additionally, PBS-treated aged mice showed a significant elevation in endplate score (Figure. 4h), as well as an increased distribution of MMP13 and ColX within the endplates when compared to young mice (Figure. 4i, 4j). Furthermore, TRAP staining revealed a significant increase in TRAP+ osteoclasts within the endplates of PBS-treated aged mice as compared to young mice (Figure. 4k).</p><fig id="sa4fig5" position="float"><label>Author response image 5.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-sa4-fig5-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(4) What is the figure legend of Figure 7?</p></disp-quote><p>The legend for Figure 7 (as below) is included in a separate PDF file labeled 'Figures and Legends.' We have carefully checked the revised manuscript and made sure all the legends are included.</p><p>âFig. 7. (a) Representative images of immunofluorescent analysis of CD31, an angiogenesis marker (green), Emcn, an endothelial cell marker (red) and nuclei (DAPI; blue) of adult sham, LSI and aged mice injected with PBS or ABT263. (b) Quantitative analysis of the intensity mean value of CD31 per mm2 in sham, LSI mice treated with PBS or ABT263. (c) Quantitative analysis of the intensity mean value of CD31 per mm2 in aged mice treated with PBS or ABT263. (d) Quantitative analysis of the intensity mean value of Emcn per mm2 in sham, LSI mice treated with PBS or ABT263. (e) Quantitative analysis of the intensity mean value of Emcn per mm2 in aged mice treated with PBS or ABT263. n â¥ 4 per group. Statistical significance was determined by one-way ANOVA, and all data are shown as means Â± standard deviations. â</p><disp-quote content-type="editor-comment"><p>(5) In &quot;Mice&quot; section, an Ethical code is suggested to be added.</p></disp-quote><p>We appreciate the reviewer's comments. In accordance with your suggestion, we have included the Johns Hopkins University animal protocol number in the revised manuscript. The relevant paragraph has been updated to read: âAll mice were maintained at the animal facility of The Johns Hopkins University School of Medicine (protocol number: MO21M276).â</p><disp-quote content-type="editor-comment"><p>(6) In &quot;Methods&quot; section, please indicate the primers of GAPDH.</p></disp-quote><p>We apologize for the absence of the GAPDH primers. Upon review, the GAPDH primers used were as follows: forward primer <named-content content-type="sequence">5'-ATGTGTCCGTCGTGGATCTGA-3'</named-content> and reverse primer <named-content content-type="sequence">5'-ATGCCTGCTTCACCACCTTCTT-3'</named-content>. These primer sequences have been included in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(7) Preosteoclasts are regarded to be closely related to H-type vessel growth, so do the authors have any comments on this? Any difference or correlation between SnCs and preosteoclasts?</p></disp-quote><p>The pre-osteoclast plays a crucial role in secreting anabolic growth factors that facilitate H-type vessel formation, osteoblast chemotaxis, proliferation, differentiation, and mineralization. The osteoclast represents the terminal differentiation phase, ultimately leading to the induction of resorption.</p><p>Senescent cells, including senescent osteoclasts, are characterized by permanent cell cycle arrest and changes in their secretory profile, which can impact their function. In the context of osteoclasts, senescence can lead to a reduction in bone resorption capacity and impaired bone remodeling. Senescent osteoclasts are believed to contribute to age-related bone loss and bonerelated diseases, such as osteoporosis.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>This research article reports that a greater number of senescent osteoclasts (SnOCs), which produce Netrin-1 and NGF, are responsible for innervation in the LSI and aging animal models.</p><p>Strengths:</p><p>The research is based on previous findings in the authors' lab and the fact that the IVD structure was restored by treatment with ABT263. The logic is clear and clarifies the pathological role of SnOCs, suggesting the potential utilization of senolytic drugs for the treatment of LBP. Generally, the study is of good quality and the data is convincing.</p><p>Weaknesses:</p><p>There are some points that can be improved:</p><p>(1) Since this work primarily focuses on ABT263, it resembles a pharmacological study for this drug. It is preferable to provide references for the ABT263 concentration and explain how the administration was determined.</p></disp-quote><p>Thank you for your comment. ABT263 has been extensively employed in diverse research studies12-15. The concentration and administration of ABT263 followed the protocol outlined in the published paper13. The reference on how to use ABT263 is cited in the method section: âABT263 was administered to mice by gavage at a dosage of 50 mg per kg body weight per day (mg/kg/d) for a total of 7 days per cycle, with two cycles conducted and a 2-week interval between them39â.</p><disp-quote content-type="editor-comment"><p>(2) It would strengthen the study to include at least 6 mice per group for each experiment and analysis, which would provide a more robust foundation.</p></disp-quote><p>Thank you for your comment here. In response, we conducted a new set of experiments, augmenting the majority of the sample size to six, and updated the corresponding statistical data in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(3) In Figure 4, either use &quot;adult&quot; or &quot;young&quot; consistently, but not both. Additionally, it's important to define &quot;sham,&quot; &quot;young,&quot; and &quot;adult&quot; explicitly in the methods section.</p></disp-quote><p>Thank you for your comment. We have addressed the inconsistency in the labeling of Figure 4. Additionally, we have explicitly defined &quot;sham,&quot; &quot;young,&quot; and &quot;adult&quot; in the methods section as follows: The control group (sham group) for the LSI group refers to C57BL/6J mice that did not undergo LSI surgery, while the control group (young group) for the Aged group refers to 4-month-old C57BL/6J mice.</p><fig id="sa4fig6" position="float"><label>Author response image 6.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-sa4-fig6-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(4) Assess the protein expression of Netrin 1 and NGF.</p></disp-quote><p>Thank you for your comment here. We employed ELISA to assess the protein expression of Netrin-1 and NGF in the L3 to L5 endplates. The data revealed that compared to the young sham mice, LSI was associated with significantly greater protein expression of Netrin1 and NGF, which was substantially attenuated by ABT263 treatment in LSI mice (Supplementary Fig. 2a, 2b)</p><fig id="sa4fig7" position="float"><label>Author response image 7.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92889-sa4-fig7-v1.tif"/></fig><p>Reference</p><p>(1) Bian, Q. et al. Excessive Activation of TGFbeta by Spinal Instability Causes Vertebral Endplate Sclerosis. Sci Rep 6, 27093, doi:10.1038/srep27093 (2016).</p><p>(2) Bian, Q. et al. Mechanosignaling activation of TGFbeta maintains intervertebral disc homeostasis. Bone Res 5, 17008, doi:10.1038/boneres.2017.8 (2017).</p><p>(3) Papadakis, M., Sapkas, G., Papadopoulos, E. C. &amp; Katonis, P. Pathophysiology and biomechanics of the aging spine. Open Orthop J 5, 335-342, doi:10.2174/1874325001105010335 (2011).</p><p>(4) Rodriguez, A. G. et al. Morphology of the human vertebral endplate. J Orthop Res 30, 280-287, doi:10.1002/jor.21513 (2012).</p><p>(5) Taher, F. et al. Lumbar degenerative disc disease: current and future concepts of diagnosis and management. Adv Orthop 2012, 970752, doi:10.1155/2012/970752 (2012).</p><p>(6) Fields, A. J., Liebenberg, E. C. &amp; Lotz, J. C. Innervation of pathologies in the lumbar vertebral end plate and intervertebral disc. Spine J 14, 513-521, doi:10.1016/j.spinee.2013.06.075 (2014).</p><p>(7) Hand, R. A. &amp; Kolodkin, A. L. Netrin-Mediated Axon Guidance to the CNS Midline Revisited. Neuron 94, 691-693, doi:10.1016/j.neuron.2017.05.012 (2017).</p><p>(8) Moore, S. W., Zhang, X., Lynch, C. D. &amp; Sheetz, M. P. Netrin-1 attracts axons through FAK-dependent mechanotransduction. J Neurosci 32, 11574-11585, doi:10.1523/JNEUROSCI.0999-12.2012 (2012).</p><p>(9) Serafini, T. et al. Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system. Cell 87, 1001-1014, doi:10.1016/s0092-8674(00)81795-x (1996).</p><p>(10) Forcet, C. et al. Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent MAPK activation. Nature 417, 443-447, doi:10.1038/nature748 (2002).</p><p>(11) Shu, T., Valentino, K. M., Seaman, C., Cooper, H. M. &amp; Richards, L. J. Expression of the netrin-1 receptor, deleted in colorectal cancer (DCC), is largely confined to projecting neurons in the developing forebrain. J Comp Neurol 416, 201-212, doi:10.1002/(sici)1096-9861(20000110)416:2&lt;201::aid-cne6&gt;3.0.co;2-z (2000).</p><p>(12) Born, E. et al. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation 147, 650-666, doi:10.1161/CIRCULATIONAHA.122.058794 (2023).</p><p>(13) Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 22, 78-83, doi:10.1038/nm.4010 (2016).</p><p>(14) Lim, S. et al. Local Delivery of Senolytic Drug Inhibits Intervertebral Disc Degeneration and Restores Intervertebral Disc Structure. Adv Healthc Mater 11, e2101483, doi:10.1002/adhm.202101483 (2022).</p><p>(15) Yang, H. et al. Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis. Aging (Albany NY) 12, 12750-12770, doi:10.18632/aging.103177 (2020).</p></body></sub-article></article>